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Enveloped viruses utilize their spike glycoproteins to mediate entry into the target 
cells. The first step requires binding of the viral spike to the receptor on the surface of 
the target cells. The binding of the virus to the host receptor is further enhanced in the 
presence of attachment factors. The final process in the entry event requires the fusion 
of the host and cell membranes to deliver the viral payload. This is mediated by the 
fusion machinery of the viral spike and can be triggered by receptor binding, 
proteolytic activity and/or low pH. 
 The virus family Coronavirdae is a representative of enveloped viruses that 
cause respiratory disease in a wide range of animal hosts. Coronaviruses like the 
severe acute respiratory syndrome  (SARS) virus and the infectious bronchitis virus 
(IBV) represent some of the common coronaviruses that have had a negative impact 
on the health of humans and the poultry industry. It is therefore key that we 
understand the mechanisms by which these viruses gain entry into their hosts in order 
to develop specific therapeutics in the event of an outbreak. 
 In this dissertation, we analyzed two domains within the S2 domain of the 
severe acute respiratory syndrome  (SARS) virus spike protein. We employed a series 
of mutagenic analysis as well as fusion and pseudoviral infection assays to observe 
that not only are these domains conserved across the Coronaviridae, but they may 
function as a potential viral fusion peptide in one domain and a critical member of the 
fusion signaling process in another domain.  
  We also investigated the entry requirements of the infectious bronchitis virus 
(IBV). This work combined FACS, fluorescence and competitive assays to observe the 
use of heparan sulfate as an attachment factor for the Beaudette strain of IBV. This 
work may further add to the rationale for the promiscuity of this lab-adapted strain of 
IBV because the virus can infect primary chicken cells as well as most cells exposed 
to the virus. 
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CHAPTER 1 
INTRODUCTION 
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Viral surface glycoproteins and their roles in mediating entry through receptor 
binding and membrane fusion.  
 Viral entry refers to the sum of processes evolved by viruses to efficiently 
deliver their genome and accessory proteins in a replication competent form into the 
host cell.  
In enveloped viruses, this process of entry initially begins when the virus 
attaches itself to a receptor or attachment factor via the viral spike glycoprotein. These 
receptors and attachment factors are usually cellular proteins, carbohydrates or lipids 
on host cells. Receptors and attachment factors may differ from virus to virus and 
present themselves in a manner that is abundant or cell specific. Attachment factors 
like heparan sulfate proteoglycans usually help concentrate viruses like the avian 
coronavirus Infectious bronchitis virus (IBV), herpes, dengue, papilloma and Sindbis 
viruses on the surface of cells (9, 11, 15, 20, 46, 53, 80) or in the case of HIV which 
utilizes cell surface lectins like DC-SIGN and L-SIGN through high mannose N-
linked glycans in the envelope protein (gp120) (5, 65). True receptors on the other 
hand, not only bind the virus and guide the virus down a selective cellular pathway but 
also serve as cues for conformational changes within the spike protein that may result 
in membrane fusion. One example is the HIV glycoprotein 120, which despite binding 
to lectins only undergoes conformational changes when a subunit of the virus protein 
binds to the receptor CD4 that in turn allows for interaction with co-receptors CXCR4 
or CCR5 to ultimately assume a fusion competent conformation (12, 27). 
Following receptor binding, overcoming the membrane barrier of the host is 
the next agenda of the enveloped virus. This is possible through the fusion of the viral 
and host membranes mediated by the fusion protein component of the spike 
glycoprotein. Sometimes this fusion protein is a single glycoprotein working in 
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concert with a receptor binding glycoprotein. The membrane fusion event can occur at 
the plasma membrane in a neutral pH environment were receptor binding is a trigger, 
or intracellularly after endocytosis where low pH and/or proteolysis also acts as 
additional triggers for membrane fusion. For the endocytic route, transport is usually 
by coated and non-coated clathrin pits/vesicles, caveolae, and macropinocytosis (74). 
Viruses that use the plasma membrane to gain entry can also use the endocytic route – 
for example HIV-1 and the severe acute respiratory syndrome (SARS) coronavirus. In 
both entry routes, conformational changes result in the fusion of host and viral 
membranes as the viral fusion protein assumes a stable hairpin conformation.  
Due to the diversity within the pathway to establish a stable hairpin 
conformation, there are three different classes of viral fusion proteins (Table 1.1). 
Class I fusion proteins, of which the influenza HA is the best studied, are trimers of 
hairpins with a central alpha-helical coiled-coil structure (34, 48, 75) Class II fusion 
proteins, which occur in flaviviruses and alphaviruses, represent trimers of hairpins 
composed of beta structures (44, 77) and class III fusion proteins found in the 
rhabdoviruses and herpesviruses, is a combination of some of the elements of I and II 
as it displays a central alpha-helical trimeric core similar to class I, but the fusion 
domain exposes fusion loops located at the tip of an elongated beta-sheet in 
resemblance of the class II fusion protein (35, 67). 
Despite the diversity in viral fusion proteins, one common theme is the 
exposure of a viral fusion peptide or loop (FP). Following such cues as receptor 
binding, pH or proteolytic cleavage during entry, the FP is exposed and anchors unto 
the target membrane and as the metastable fusion protein converts to a lower energy 
conformation, it allows for both the target and viral membrane to be in close proximity 
to fuse. 
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Table 1.1 Classifications of Viral Fusion Proteins (selective) (adapted from 
Weissenhorn et. al, FEBS lett., 2007) 
 
Virus Family Virus species PDB code  
Class I   
Orthomyxoviridae Influenza A virus HA 1HA0, 3HMG, 1HTM, 
1QUI 
Coronaviridae SARS coronavirus S2 2BEQ, 1WYY 
Class II   
Flaviviridae Dengue 2 and 3 virus E 1OK8, 1UZG, 10AN, 
1TG8 
Togaviridae Semliki forest virus E1 1E9W, 1RER 
Class III 
Rhabdoviridae Vesicular stomatitis 
virus G 
2GUM 
Herpesviridae Herpes simplex virus gB 2CMZ 
Fusion peptides are generally apolar sequences that are conserved within a 
virus family. Commonly found within FPs are bulky hydrophobic residues as well as 
glycine and alanine residues to confer conformational flexibility. Proof of a fusion 
peptide usually comes from mutating conserved residues within a proposed sequence 
in the context of the fusion protein and observing marked reductions in fusion activity 
compared to the wildtype activity (18, 54, 81). Also the ability of a synthetic peptide 
form of the said sequence to interact with membranes to induce fusion or identification 
  5 
of the said sequence in membrane cross-linking studies is key to identifying a fusion 
peptide.  Depending on the position of the FP in relation to the fusion unit, FPs can be 
considered N-terminal or internal (Table 1.2).  
FPs destabilize membranes by initiating stalk formation possibly by displacing 
water from the lipid-water interface which leads to reduced repulsive force between 
the fusing host and virus membranes (33, 87). 
Table 1.2 Amino acid sequences of viral fusion peptides (adapted from Earp, LJ. et. 
al. CTMI, 2004) 
 
N-terminal Virus Sequence 
Class I Influenza HA2 GLFGAIAGFIENGWEG 
 Sendai F1 FFGAVIGTIALGVATA 
 Resp. Syn. F1 FLGFLLGVGSAIASGV 
 HIV gp41 AAIGALFLFGLGAAGSTMGAA 
Internal   
Class I Ebola GP GAAIGLAWIPYFGPAA 
 ASLV gp 37 IFASILAPGVAAAQAL 
Class II SFV E1 DYQCKVYTGVYPFMWGGAYCFCD 
 TBE E DRGWGNHCGLFGKGSIVA 
Class III VSV G QGTWLNPGFPPQSCGYATV 
Along with the FP, other parts of the fusion protein play an important role in 
fusion. Regions like the membrane proximal ectodomain region (MPER), the 
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transmembrane domain (TMD), and the cytoplasmic tail (60) have all been cited as 
players in the fusion machinery.  
MPERs are located between the C-terminal heptad repeat and the TMD. 
Mostly characterized in class 1 viral fusion proteins, MPERs conserved within the 
virus family commonly contain aromatic residues. MPER sequences have been 
predicted to partition into membrane interfaces (72, 79, 81). In HIV Env, mutated 
MPER aromatic residues have been shown to cause a reduction in fusion (71). The 
mutations to the MPER are believed to abrogate the transition from a small fusion 
pore to a large one (58). HIV Env MPERs have also been shown to be a site of action 
of the T20 HIV peptide inhibitor (45). In virus fusion proteins of the SARS 
coronavirus, VSV-G, HSV-1gH, HPIV2 F and FIV, mutations to the MPER residues 
inhibited fusion (25, 28, 38, 40, 41, 84) and peptides to the regions in SARS and Ebola 
have been shown to require aromatic residues in order to destabilize membranes (68, 
70). It has also been proposed that the hydrophobicity of the MPER may serve as 
compensation for less hydrophobic FPs as is the case for several herpes virus gB 
proteins (4). 
 C-terminal to the MPER is the transmembrane domain (TMD) another region 
that is reported to be important for membrane fusion. Although studies on the TMD 
can affect folding, trimerization, surface expression and even incorporation of the 
glycoprotein into the virion, it is still important for fusion. An example, also seen in 
other fusion proteins, is the replacement of the influenza HA TMD with a GPI anchor 
which blocks fusion, particularly at the hemifusion or small pore stage (43, 55, 57, 
84). Many studies have cited factors such as key residues that are either conserved, as 
is the case for the basic residues within the TMD of retroviral glycoproteins (59, 86), 
or residues like proline or glycine, which contain helix-disrupting properties, such 
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residues are found in the middle of the TMD (17, 19) and have been reported as 
important for TMD function. Other factors such as minimal length of residues as a 
requirement for individual TMDs to function have also been reported (2, 52, 56). 
Although studies on the TMD sequences required for supporting fusion are 
inconclusive, other studies leave us with the suggestion that the TMD must span the 
viral membrane bilayer and be anchored at the inner leaflet to support fusion. 
 The cytoplasmic tail (60) ( CT)  of viral fusion proteins play important 
roles for membrane fusion within virus families. CTs can affect the ectodomain 
structure and alter fusion. One example is CT proteolytical cleavage lowering the 
energy barrier for fusion, thus causing virus fusion proteins like the HIV Env or HSV 
gB lacking a CT or truncations of the CT to fuse faster (1, 64, 82). Studies have also 
shown that CTs can serve to prevent premature fusion as observed in the interactions 
of the gp41 CT and the viral capsid gag (89). Interestingly, the membrane proximal 
regions of the CT have also been implicated to be critical for the late stages of fusion 
in a manner much like MPERs. One example observed in SARS S and subtypes of 
influenza HA is palmitoylation of cysteine residues in the membrane proximal regions 
of the CT have been shown to be important for membrane fusion (13, 62). The loss in 
fusion function that comes with the deletion of the CT or palmitoylation sites has been 
linked to the inability of the mutant fusion proteins to transition from small to large 
pores: the most energy demanding step of fusion. 
Coronaviruses 
 Coronaviruses (CoV) of the family Coronaviridae are enveloped viruses with a 
single, linear, non-segmented, positive-sense RNA genome (Figure 1.2). The viral 
genome, which ranges from 26-32 KB, encodes non-structural proteins, and four main 
structural proteins S, E, M, N and a fifth protein HE is only encoded in a subset of 
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CoVs. The S glycoprotein is responsible for receptor binding and membrane fusion. 
The E protein is an integral protein with roles in morphogenesis, assembly and 
budding. The M protein functions in viral structural integrity and assembly. The N 
protein is responsible for viral RNA encapsidation. The group 2 subgroup protein HE 
has hemagglutination, receptor binding and virion release activity.  This virus family 
has a negative impact on the lives of humans and animals as they cause respiratory and 
enteric disease within the hosts they infect. CoVs are currently divided into three 
groups based on serological and genetic data, and are further divided into subgroups 
(61) (Table 1.3). Group 1 represents viruses that infect humans, bats, cats and dogs 
while group 2 covers cattle, swine, murine, humans and bats with the severe acute 
respiratory syndrome coronavirus (SARS-CoV) being the prototype virus of this 
group. The structural protein S is a main focus of this thesis. Finally group 3, which 
cover the avian coronaviruses. We discuss in chapter 2 a possible attachment factor 
utilized by the infectious bronchitis virus (IBV). 
A distinctive feature of the CoVs is the crown shaped morphology that can be 
seen in electron microscopy images attributed to the spike glycoprotein S. It is a 
heavily glycosylated protein of 150-180 kDa and is responsible for receptor binding 
and membrane fusion. The CoV spike protein S functions in entry is the main focus 
and in the course of this thesis, we will go into detail on how domains within the spike 
protein may aid the entry process. As a major protein of importance for entry, the 
spike protein of coronaviruses has been studied in detail. The protein is dedicated to 
the delivery of the viral genome to the target cell. In order to achieve this task, it has 
two functions: binding the receptor on the host cell, and mediating the fusion of host. 
 
  
  9 
Table 1.3 Representative coronavirus species and receptors (adapted from Perlman 
et. al. Nature, 2009) 
GROUP HOST VIRUS RECEPTOR 
Group1a Bat BtCov Unknown 
 Cat FCoV, FIPV APN 
 Dog CCoV APN 
 Pig TGEV APN 
Group 1b Human HCoV-229E, NL63* APN, ACE2* 
 Pig PEDV Unknown 
Group 2a Cattle BCoV 9-O-acetylated sialic acid 
 Dog CRCoV Unknown 
 Human HCoV–HKUI, OC43 Unknown 
 Mouse MHV CEACAM 
 Pig PHEV Unknown 
Group 2b Bat BtCoV Unknown 
 Human SARS-CoV ACE2 
Group 3a Chicken IBV Unknown 
 Pheasant PhCoV Unknown 
 Turkey TCoV Unknown 
Group 3b Beluga whale SW1 Unknown 
Group 3c Bulbul BuCoV-HKU11 Unknown 
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and viral membranes for the efficient delivery of the viral genome. For these roles, the 
spike protein can be processed into two main domains, S1 and S2 respectively.  
 
 
 
Figure 1.1 a) Electron microscope image and b) Schematic of a Coronavirus. 
 
As CoVs has a wide host range (Table 1.3) the less conserved S1 region (54) 
defines the host tropism (14, 31, 36, 37, 49, 50, 73, 83, 85). For the S2 domain, 
undeniable sequence conservation is observed in the fusion component of the protein 
hinting at a conserved fusion mechanism (16, 54). S2 contains a fusion peptide, heptad 
repeats (HR1 and HR2), a membrane proximal region, a transmembrane domain and a 
short C-terminal tail, all of which have been characterized as being important for 
mediating membrane fusion (8, 10, 38, 62). 
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Severe acute respiratory syndrome (SARS) coronavirus  
The year 2002 marked the introduction of the first new infectious disease of 
the twenty-first century. A severe respiratory illness, which originated from a province 
in China, was caused by the severe acute respiratory syndrome coronavirus (SARS-
CoV). This new coronavirus with severe disease-causing capabilities in humans was 
responsible for close to 800 deaths with an overall fatality of 10% until it was brought 
under control through an effective global quarantine effort in 2003 (21, 24). 
The SARS-CoV is a group 2 coronavirus borne out of a zoonotic event from 
natural reservoir hosts like bats and palm civets (22). Entry into host cells is achieved 
through the interaction of the viral spike protein S and the host cell receptor, the 
human angiotensin-converting enzyme 2 (ACE2) (47). As the S protein is key for 
attachment and entry it is one of the most studied coronavirus proteins in the hopes 
that detailed studies may lend to the development of therapeutics/prophylactics to 
combat re-emergence of SARS-CoV or a SARS-like coronavirus into the human 
population. 
SARS-CoV S protein  
The SARS-CoV S protein functions as a trimer and is classified as a class 1 
viral fusion glycoprotein in the same company as the glycoproteins of HIV, Influenza, 
and Ebola viruses. This class of fusion proteins is trimeric and alpha-helical in 
secondary structure and can be triggered to undergo irreversible conformational 
changes in the presence of a receptor, low pH or a combination of the two (87) . 
The structure of the whole S protein has yet to be solved but the minimal 
receptor-binding domain (RBD) in S1 has been mapped in crystallographic studies to 
residues 318-510 (3). The crystallographic study of the RBD in complex with the 
receptor ACE2, revealed the presence of a tyrosine rich receptor binding motif as well 
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as multiple cysteines in disulphide bonds of which cysteines 479 and 487 are 
attributed the responsibility of SARS disease progression and tropism (51, 66). SARS-
CoV S has also been shown to gain entry with the use of DC-SIGN and L-SIGN (32, 
42) however their function as a receptor remains to be further verified. 
 The fusion component of the S protein lies in the S2 domain. This region is 
highly conserved within the family and is structurally similar to the other class 1 
fusion proteins as S2 contains a fusion peptide, two heptad repeat regions, a membrane 
proximal region, a transmembrane region and a cytoplasmic tail. S protein of SARS-
CoV being mostly proteolytically unprocessed at the boundary of S1/S2 is a character 
that sets the S protein apart from other class 1 fusion proteins. Also is the fact that the 
fusion peptide of SARS-CoV and other coronaviruses are internal at a yet unknown 
location while that of other class 1fusion proteins like HIV and influenza are N-
terminal of the membrane anchored subunit. It is considered that the little cleavage 
that occurs at the S1/S2 boundary is not directly related to fusion peptide exposure for 
SARS-CoV or any other CoV (7, 76, 90). 
 Although the mature SARS S protein is proteolytically uncleaved during 
maturation, proteolysis is required to facilitate membrane fusion. In the presence of 
proteolytic activity it has been shown that SARS-CoV can gain entry via two 
pathways: at the cell surface as mediated by trypsin-like enzymes or by the endosomal 
pathway through the activity of cathepsin L in endosomes (7, 23, 39). Recently, it has 
been published that within S2 lies a region of proteolysis that has been proposed to be 
part of a cleavage event that activates the S protein (6, 91). 
The multiple investigations on the proteolytic activity occuring within S2, has 
reopened the controversial discussion about the position of the coronavirus fusion 
peptide. Previous reports using Wimley and White interfacial hydrophobicity scales 
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have identified amino acids 770-788 and 858-886 as putative fusion peptides (29, 30, 
69). Synthetic peptides corresponding to these regions of S2 were all shown to induce 
fusion and leakage of vesicles as well as adopt secondary structure in the presence of 
lipids. Chapter 2 adds to the discussion of the identity of the coronavirus fusion 
peptide by presenting the region S798-F815 as a putative coronavirus fusion peptide. 
Our proposal that this region may serve as the fusion peptide is not only based on 
membrane interactions and secondary structure as seen in previous studies, but also 
based on the strong conservation within the family and the proximity to the recently 
publish cleavage site within S2. 
Finally the redox status of the S protein during entry has also been taken into 
consideration. There are 39 cysteines in S capable of disulfide bonds. Studies have 
shown cysteines have played key roles in receptor binding and membrane fusion (62, 
63, 66). Other investigations point to the importance of redox changes occurring 
during conformational rearrangements of coronavirus proteins (26, 78).  In chapter 3, 
we introduce a cysteine-flanked domain in S2 that is important for membrane fusion. 
We propose this region forms a disulfide linked loop structure that is part of the fusion 
machinery within S2 and set out to characterize it. 
Infectious Bronchitis virus 
 The Infectious Bronchitis virus (IBV) is an avian coronavirus that targets the 
respiratory and uro-genital tract. The virus can spread to different organs throughout 
the chicken. Infection initially causes respiratory disease in the infected birds but can 
affect the renal systems of chickens. Poultry industries have suffered great losses as 
IBV infection causes a reduction in weight gain and also drops egg production in 
layers and breeders. 
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 The natural receptor for IBV remains unknown but the entry requirements for 
IBV are still being investigated. To date, the virus entry process has been associated 
with a low pH environment (16). Cell surface sialic acid has also been reported as a 
requirement for IBV entry (88) but in the absence of a HE protein in IBV that is 
required for sialic acid binding, it is most likely interacting with sialic acid as a non 
specific attachment factor rather than a functional receptor.  
IBV can be propagated in embryonated eggs and transiently in primary chicken 
embryo kidney cells. In contrast to the clinical strains of IBV that infect only primary 
cells, the Beaudette strain of IBV has an extensive tropism in cell culture and 
efficiently infects various cell types, including BHK-21 cells and is used as an in vitro 
infection model.  
With the spike protein S being the sole determinant of the extended species 
tropism, a bioinformatic analysis of the S protein of the Beaudette strain compared to 
the clinical IBV strains revealed a heparin binding consensus sequence unique to the S 
protein of Beaudette. In chapter 4, we propose that this region is responsible for 
binding cell surface heparan sulfate (HS) as an attachment factor aiding extended 
tropism observed in this strain. 
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Abstract 
Many viral fusion proteins are primed by proteolytic cleavage near their fusion 
peptides. While the coronavirus (CoV) spike (S) protein is known to be cleaved at the 
S1/S2 boundary, this cleavage site is not closely linked to a fusion peptide. However, a 
second cleavage site has been identified in the severe acute respiratory syndrome CoV 
(SARS-CoV) S2 domain (R797). Here, we investigated whether this internal cleavage 
of S2 exposes a viral fusion peptide. We show that the residues immediately C-
terminal to the SARS-CoV S2 cleavage site SFIEDLLFNKVTLADAGF are very 
highly conserved across all CoVs. Mutagenesis studies of these residues in SARS-
CoV S, followed by cell-cell fusion and pseudotyped virion infectivity assays, showed 
a critical role for residues L803, L804, and F805 in membrane fusion. Mutation of the 
most N-terminal residue (S798) had little or no effect on membrane fusion. 
Biochemical analyses of synthetic peptides corresponding to the proposed S2 fusion 
peptide also showed an important role for this region in membrane fusion and 
indicated the presence of alpha-helical structure. We propose that proteolytic cleavage 
within S2 exposes a novel internal fusion peptide for SARS-CoV S, which may be 
conserved across the Coronaviridae. 
Introduction 
The severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in 2003 as a 
significant threat to human health, and CoVs still represent a leading source of novel 
viruses for emergence into the human population. The CoV spike (S) protein mediates 
both receptor binding (via the S1 domain) and membrane fusion (via the S2 domain) 
and shows many features of a class I fusion protein, including the presence of distinct 
heptad repeats within the fusion domain (37). A critical feature of any viral fusion 
protein is the so-called "fusion peptide," which is a relatively apolar region of 15 to 25 
amino acids that interacts with membranes and drives the fusion reaction (9, 34, 38). 
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Fusion peptides can be classified as N-terminal or internal, depending on their location 
relative to the cleavage site of the virus fusion protein (23). One key feature of viral 
fusion peptides is that within a particular virus family, there is high conservation of 
amino acid residues; however, there is little similarity between fusion peptides of 
different virus families (26). Despite these differences, some common themes do 
emerge, including a high level of glycine and/or alanine residues, as well as critical 
bulky hydrophobic amino acids. In several cases, the fusion peptide is known to 
contain a central "kink." In the case of influenza virus hemagglutinin (HA), which is a 
classic example of an N-terminal fusion peptide, the N- and C-terminal parts of the 
fusion peptide (which are alpha-helical) penetrate the outer leaflet of the target 
membrane, with the kink at the phospholipid surface. The inside of the kink contains 
hydrophobic amino acids, with charged residues on the outer face (18). Internal fusion 
peptides (such as Ebola virus [EBOV] GP) often contain a conserved proline near their 
centers but also require a mixture of hydrophobic and flexible residues similar to N-
terminal fusion peptides (9, 11). It is believed that the kinked fusion peptide sits in the 
outer leaflet of the target membrane and possibly induces positive curvature to drive 
the fusion reaction (22). It is important to note that, despite the presence of key 
hydrophobic residues, viral fusion peptides often do not display extensive stretches of 
hydrophobicity and can contain one or more charged residues (8). Ultimately, fusion 
peptide identification must rely on an often complex set of criteria, including 
structures of the fusion protein in different conformations, biophysical measurements 
of peptide function in model membranes, and biological activity in the context of virus 
particles.  
To date, the exact location and sequence of the CoV fusion peptide is not known (4); 
however, by analogy with other class I viral fusion proteins, it is predicted to be in the 
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S2 domain. Overall, three membranotropic regions in SARS-CoV S2 have been 
suggested as potential fusion peptides (14, 17). Based on sequence analysis and a 
hydrophobicity analysis of the S protein using the Wimley-White (WW) interfacial 
hydrophobic interface scale, initial indications were that the SARS-CoV fusion peptide 
resided in the N-terminal part of HR1 (heptad repeat 1) (5, 6), which is conserved 
across the Coronaviridae. Mutagenesis of this predicted fusion peptide inhibited fusion 
in syncytia assays of S-expressing cells (28). This region of SARS-CoV has also been 
analyzed by other groups in biochemical assays (16, 17, 29) and defined as the WW II 
region although Sainz et al. (29) identified another less conserved and less 
hydrophobic region (WW I) as being more important for fusion. Peptides 
corresponding to this region have also been studied in biochemical assays by other 
groups (13). In addition, a third, aromatic region adjacent to the transmembrane 
domain (the membrane-proximal domain) has been shown to be important in SARS-
CoV fusion (15, 20, 25, 30). This membrane-proximal domain likely acts in concert 
with a fusion peptide in the S2 ectodomain to mediate final bilayer fusion once 
conformational changes have exposed the fusion peptide in the ectodomain. To date, 
there is little or no information on the fusion peptides of CoVs other than SARS-CoV, 
except for the identification of the N-terminal part of the mouse hepatitis virus (MHV) 
S HR1 domain as a putative fusion peptide based on sequence analysis (6). In none of 
these cases (for SARS-CoV or MHV) is the role of these sequences as bone fide fusion 
peptides established.  
The majority of class I fusion proteins prime fusion activation by proteolytic 
processing, with the cleavage event occurring immediately N-terminal to the fusion 
peptide (21). In the case of SARS-CoV, early reports analyzing heterologously 
expressed SARS-CoV spike protein indicated that most of the protein was not cleaved 
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(31, 39) but that there was some possibility of limited cleavage at the S1-S2 boundary 
(39). However, it is generally considered that S1-S2 cleavage is not directly linked to 
fusion peptide exposure in the case of SARS-CoV or any other CoV (4). Recently, 
however, it has been shown that SARS-CoV S can be proteolytically cleaved at a 
downstream position in S2, at residue 797 (2, 36). Here, we investigated whether 
cleavage at this internal position in S2 might expose a domain with properties of a viral 
fusion peptide. We carried out a mutagenesis study of SARS-CoV S residues 798 to 
815 using cell-cell fusion and pseudovirus assays, as well as lipid mixing and 
structural studies of an isolated peptide, and we show the importance of this region as a 
novel fusion peptide for SARS-CoV. 
Materials and Methods 
Cell culture. BHK-21, Vero E6, and 293T cells obtained from the American Type 
Culture Collection were used in this study. All cells were maintained in Dulbecco's 
modified Eagle's medium (DMEM; Cellgro) containing 10% fetal bovine serum, 100 
units/ml penicillin, and 10 µg/ml streptomycin (complete DMEM).  
Generation of mutant SARS-CoV spike glycoproteins. Site-directed mutagenesis 
was carried out on the spike protein expressing vector pcDNA3.1-SARS-CoV S 
(kindly provided by Michael Farzan, New England Primate Research Center) via PCR, 
using primers obtained from IDT Technologies. Mutations were then confirmed by 
sequencing using an Applied Biosystems Automated 3730 DNA Analyzer at the 
Cornell University Life Sciences Core Laboratories Center.  
Analysis of SARS-CoV S cell surface expression. BHK-21 cells were grown on six-
well plates and transfected with 1 µg of wild-type or mutant spike protein-expressing 
plasmids using Lipofectamine 2000 (Invitrogen) for 36 h at 32°C. Transfected cells 
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were washed twice with cold phosphate-buffered saline and then labeled with 250 
µg/ml sulfo-NHS-SS-biotin [sulfosuccinimidyl 2-(biotinamido)-ethyl-1,3-
dithiopropionate; Pierce] for 30 min on ice. Cold glycine solution (50 mM) was added 
to the cells three times at 5-min intervals to quench unlabeled free biotin, followed by 
a phosphate-buffered saline wash. The cells were lysed in 500 µl of lysis buffer (Tris-
buffered saline containing 1% NP-40 and complete protease inhibitor mixture; Roche 
Applied Science). Surface proteins were affinity purified using immobilized 
NeutraAvidin beads (Pierce) overnight at 4°C. NeutraAvidin beads were then washed 
with lysis buffer, followed by the addition of sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE) sample loading buffer containing 100 mM 
dithiothreitol. The surface expression was analyzed by Western blotting using the anti-
C9 epitope tag monoclonal antibody Rho 1D4 (National Cell Culture Center, 
Minneapolis, MN), and images were obtained and quantified using an LAS-3000 Mini 
Fuji film imaging system and software (Fuji Photo Film Co., Ltd). The biotinylation 
assay was repeated three times, and results from the Western blotting quantifications 
were plotted using Sigma Plot, version 9.0 (Systat Software). 
Syncytia formation and visualization. BHK-21 cells in 24-well plates were 
cotransfected with pcDNA3.1-SARS-CoV S plasmid encoding wild-type or mutant 
spike protein and a plasmid encoding ACE2, the SARS-CoV receptor, using 
Lipofectamine 2000 (Invitrogen) for 24 h at 32°C. Cells were treated with 2 µg/ml of 
trypsin in serum free medium for 30 min to induce syncytia formation, and then the 
medium was replaced with complete DMEM for 1 h. The cells were then fixed using 
3% paraformaldehyde and prepared for indirect immunofluorescence microscopy 
using the monoclonal SARS-CoV S antibody 341CD (NIH Biodefense and Emerging 
Infections Research Resources Repository) and Alexa Fluor 488-labeled anti-mouse 
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secondary antibody (Invitrogen-Molecular Probes). Images were captured using a 
Nikon E600 microscope 20x Plan Apo objective (numerical aperture, 0.75) equipped 
with a SensiCam EM camera (Cooke Corp.) and using IP Lab software (Scanalytics).  
Quantitative cell-cell fusion assay. BHK-21 cells were grown in 24-well plates and 
cotransfected with wild-type or mutant spike protein-expressing plasmids and a 
plasmid encoding luciferase under the control of a T7 promoter, using Lipofectamine 
2000 (Invitrogen) for 24 h at 32°C. Vero E6 cells in a 60-mm dish were also 
transfected with a plasmid encoding the T7 polymerase. After 24 h the BHK-21 cells 
were overlaid with Vero E6 cells and incubated for 3 h. Cells were treated with serum-
free medium containing 2 µg/ml trypsin to induce fusion, the medium was replaced 
with complete DMEM after 30 min. At 6 h postinduction, cells were lysed and assayed 
for luciferase activity using a luciferase assay kit (Promega) and a Glomax 20/20 
luminometer (Promega) to measure light emission.  
Spike protein pseudotyped virion production. Pseudotyped virions were generated 
using plasmids kindly provided by Jean Dubuisson (Lille Pasteur Institute, France). 
293T cells were cotransfected with a murine leukemia virus (MLV)-based transfer 
vector encoding luciferase, an MLV Gag-Pol packaging construct, and pcDNA3.1-
SARS-CoV S, a plasmid encoding wild-type or mutant spike envelope glycoprotein, 
using Exgen 500 (Fermentas) as recommended. After incubation for 72 h at 32°C, 
supernatants were collected and filtered through a 0.45-µm-pore-size membrane. The 
level of spike protein incorporation was confirmed by polyethylene glycol (PEG) 
concentration, centrifugation, and Western blot analysis. A total of 600 µl of filtered 
supernatant was mixed with 200 µl of 40% PEG and centrifuged for 30 min at 4,000 
rpm at 4°C. The pellet was redissolved in SDS-PAGE sample loading buffer 
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containing 100 mM dithiothreitol and blotted in the same manner as described above 
in the cell surface biotinylation assay.  
Spike protein pseudotyped virion infectivity assays. Equal levels of pseudoparticles 
were used based on the level of spike protein pseudotype virions quantified by 
Western blotting, as described above. For a typical infection assay, spike protein 
pseudotype virions containing wild-type or mutant glycoproteins were bound for 2 h in 
RPMI medium containing 0.2% bovine serum albumin (BSA)-20 mM HEPES to Vero 
E6 cells at 4°C. Medium was exchanged for complete DMEM and incubated for 48 h 
at 37°C. The cells were then lysed, and luciferase activity was measured using the 
same methods as the quantitative cell-cell fusion assay. In a trypsin-mediated cell 
surface infectivity assay, Vero E6 cells were first preincubated with 25 mM NH4Cl for 
1 h at 37°C. Pseudotyped virions were then bound for 2 h in RPMI medium containing 
0.2% BSA, 20 mM HEPES, and 25 mM NH4Cl at 4°C. The cells were then warmed 
up with the addition of prewarmed RPMI medium containing 5 µg/ml trypsin, 0.2% 
BSA, 20 mM HEPES, and 25 mM ammonium chloride for 5 min at 37°C in a water 
bath.  
Peptides.  
The SARS-CoV S2 fusion peptides SFIEDLLFNKVTLADAGFMKQYGCGKKKK, 
SFIEDLLFGCGKKKK, and SFIEDAAAGCGKKKK were synthesized using solid-
phase techniques by New England Peptide (Gardner, MA). The GCGKKKK linker 
was included to promote liposome association as described for the host-guest fusion 
peptide system of Han et al. (19). Purity as determined by high-performance liquid 
chromatography was greater than 95%, and mass identification was performed by 
matrix-assisted laser desorption ionization-time of flight mass spectrometry. Peptides 
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were resuspended to 5 mg/ml in sterile MilliQ water. Control peptides were treated 
identically and had the sequence SIRYSFCGNGRHV for circular dichroism (CD) 
spectroscopy experiments and GCGKKKK for lipid-mixing experiments.  
Liposomes. 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1-palmitoyl-
2-oleoyl-sn-glycero-3-[phospho-L-serine] (sodium salt) (POPS), and cholesterol were 
purchased from Avanti Polar Lipids (Alabaster, AL). Labeled phospholipids N-(7-
nitrobenz-2-oxa-1,3-diazol-4-yl)-1,2-dihexadecanoyl-sn-glycero-3-phospho- 
ethanolamine, triethylammonium salt (NBD-PE) and lissamine rhodamine B 1,2-
dihexadecanoyl-sn-glycero-3-phosphoethanolamine, triethylammonium salt (Rho-PE) 
were purchased from Invitrogen (Carlsbad, California). Large unilamellar vesicles 
were prepared according to the extrusion method. Lipid films were obtained by 
subjecting chloroform-dissolved lipid mixtures at a ratio of 1:3:1 of POPC-POPS-
cholesterol to high vacuum overnight. Lipid films were resuspended by the addition of 
fusion buffer (5 mM HEPES, 5 mM morpholinethanesulfonic acid, 5 mM sodium 
succinate, 150 mM sodium chloride, pH 7) to a 5 or 10 mM lipid concentration and 
incubated for 15 min at room temperature, followed by vortexing for 15 min. 
Liposomes were then subjected to 10 freeze-thaw cycles, followed by 11 cycles of 
extrusion through a 0.1-µm-pore-size polycarbonate membrane using an Avanti mini-
extruder. Liposomes labeled with the fluorescent resonance energy transfer (FRET) 
pairs Rho-PE and NBD-PE were made in the same manner with the addition of 0.6% 
each of NBD-PE and Rho-PE to the chloroform-dissolved lipid mixture.  
Lipid-mixing assay. Lipid mixing was determined using the method of Struck et al. 
(32). Unlabeled and labeled liposomes were mixed at a 4:1 ratio to a total 
concentration of 110 µM lipid in fusion buffer at pH 7.0. Hydrochloric acid was added 
to the solution until the desired pH was achieved. To initiate fusion, peptide was added 
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to the specified concentration. To end the reaction and obtain a measurement of 100% 
lipid mixing, reduced Triton X-100 was added to a final concentration of 0.2%. 
Changes in fluorescence were measured using a QM-6SE spectrofluorimeter (Photon 
Technology International, Birmingham, NJ) with excitation set at 467 nm and emission 
monitored at 530 and 581 nm. The extent of lipid mixing was determined using the 
following formula: F(%) = [(ft – f0)/(f100 – f0)] x 100, where ft is the fluorescence 
measurement at time t, f0 is the initial fluorescence, and f100 is the fluorescence after 
the addition of reduced Triton X-100. All measurements were taken in triplicate and 
averaged.  
CD spectroscopy. Spectra were obtained using an Aviv Biomedical CD spectrometer, 
model 202-01, equipped with a thermoelectric temperature controller. Spectra were 
obtained at a 50 µM peptide concentration in 50% trifluoroethanol (TFE) at 37°C. A 
wavelength range of 190 to 260 nm and averaging time of 2 s were used. Alpha helical 
content was calculated using the following formula: fH = (θ222 – θC)/(θ H –θC) 
Where θC =2220-53T and θH =(250T-44000)(1-3/n), T is the temperature in Celsius 
and n is the number of residues in the peptide. 
Results 
Bioinformatics and mutational analysis of the proposed CoV fusion peptide. 
Based on the internal S2 cleavage site of SARS-CoV at R797, a predicted fusion 
peptide exposed by such cleavage would start at residue serine 798 and extend to 
phenylalanine 815. One common feature of viral fusion peptides is that they show a 
high degree of conservation within a virus family (26). We therefore performed a 
multiple sequence alignment of the spike protein of representative CoVs. This 
bioinformatics analysis showed a very high degree of conservation in the site of the 
proposed S2 fusion peptide (residues 798 to 815) (Fig.2.1A). Indeed, residues 798 to 
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815 represent some of the most conserved spike protein residues across the 
Coronaviridae. In particular, the domain IEDLLF shows >95% identity, with only 
limited and very conservative substitutions (I-L/F, L-I/V, and F-Y) in the core 
hydrophobic residues and with 100% conservation of the initial serine residue (Fig. 
2.1B). This highly conserved region is consistent with the requirements for a viral 
fusion peptide as it contains both small and bulky hydrophobic residues interspersed 
with more hydrophilic residues. While the juxtamembrane region is also highly 
conserved, the other proposed SARS-CoV S fusion peptides (WWI and WWII) show a 
much lower degree of conservation (Fig. 2.1B). 
To test the fusogenic properties of the conserved S2 region (residues 798 to 815), 
mutations were introduced into a SARS-CoV S protein-expressing vector to generate 
the following mutants: S798A, F799A, I800A, E801A, D802A, L803A, L804A, 
F805A, N806A, K807A, V808A, T809A, L810A, D812A, G814A, and F815A (Fig. 
2.1B). In order to evaluate the effect of point mutants on the fusogenic properties of 
SARS-CoV S protein, we first verified the cell surface expression of the mutants. The 
level of surface expression of the alanine point mutants was verified quantitatively 
after transfection of expression vectors bearing mutant or wild-type S protein in BHK-
21 cells, at both 37°C and 32°C, followed by biotinylation and immunoblotting. At 
37°C, we observed medium to low levels of surface expression of many of the mutants 
(data not shown), but at 32°C we were able to observe all mutants expressing at >65% 
of wild-type levels, and in most cases expression was >85% of wild-type levels 
(Fig.2.2). 
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Figure. 2.1. Bioinformatics analysis of the CoV S protein and the proposed S2 
fusion peptide. (A) A quantitative multiple sequence alignment of the S protein from 
representative CoVs was performed using the program AlignX, a component of 
Vector NTI 10.3.1 (Invitrogen), which uses a modified Clustal W algorithm. The 
proposed S2 fusion peptide and other regions of interest have been identified with bars 
or arrows to show their location within the S gene and their various degrees of 
conservation across the CoV family. (B) A multiple sequence alignment of the S 
protein from representative CoVs was performed using AlignX as above. Conserved 
residues within the proposed S2 fusion peptide region are indicated in bold. 
Underlining indicates residues showing conserved properties.  
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Figure  2.2. Effect of alanine point mutants on spike protein surface expression. 
 BHK cells were transfected with plasmids encoding wild-type SARS-CoV S or 
alanine mutants. The cells were labeled with sulfo-NHS-SS-biotin and lysed. Lysates 
were affinity purified with NeutraAvidin beads and resolved by SDS-PAGE and 
Western blotting using anti-S monoclonal antibody C9. The biotinylation assay was 
repeated three times, and the results from the Western blotting were quantified using 
IP Lab software and plotted in Sigma Plot, version 9.0. Error bars represent standard 
deviations of the means. WT, wild type. 
With high-level expression at the cell surface verified, we were then able to evaluate 
how the mutated residues might affect membrane fusion. Taking advantage of trypsin 
as a fusion trigger for the spike protein, we employed two methods of determining cell-
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cell fusion. The first method was a qualitative assessment of the mutant's ability to 
form syncytia in the presence of trypsin, which was performed by analyzing BHK-21 
cells cotransfected with wild-type or mutant spike protein and ACE2, the SARS-CoV 
host cell receptor (Fig. 2.3). We observed a range of fusion events upon treatment with 
trypsin. In wild-type SARS-CoV S-expressing cells, trypsin treatment resulted in the 
production of large syncytia in comparison to nontreated cells expressing the spike 
protein. Mutation of the core conserved residues, i.e., I800A, L803A, L804A, F805A, 
K807A, and V808A, produced only limited fusion events in comparison to wild-type 
trypsin-treated cells, with the degree of syncytia comparable in some instances to wild-
type levels in non-trypsin-treated cells. We also observed that the L810A, D812A, 
G814A, and F815A mutants in the C-terminal portion of the fusion peptide also 
displayed poor syncytia. In other alanine substitution mutants, i.e., S798A, D802A, 
N806A, and T809A, we saw similar levels of fusion in cells activated by trypsin and 
the wild-type protein.  
In order to quantify the extent of the SARS S protein-mediated membrane fusion 
activity, a luciferase-based assay system was employed. In this assay, BHK-21 cells 
were cotransfected with wild-type or mutant spike protein along with a T7 
polymerase-driven luciferase gene and overlaid with Vero E6 cells transfected with the 
T7 polymerase gene. Fusion was induced by trypsin treatment, and the degree of 
luciferase activity after induction of fusion was used as an indicator of the fusogenic 
ability of the mutant SARS-CoV S protein in comparison to the wild type (Fig.2.4). 
We observed a variation of activity in response to mutation of the conserved S2 region 
(residues 798 to 815). 
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Figure 2.3. Syncytium formation mediated by mutant spike proteins.  
BHK cells were transfected with plasmids encoding wild-type (WT) SARS-CoV S or 
alanine mutants and ACE2. Fusion was induced using medium containing 2 µg/ml 
trypsin as described in Materials and Methods, and syncytia were visualized by 
immunofluorescence microscopy using anti-S antibodies (green signal). Nuclei were 
counterstained with Hoechst 33264 (blue signal). 
Mutation of the core conserved residues, such as I800, L803, L804, F805, K807, 
V808, L810, D812, G814, and F815, resulted in luciferase activity that was 20% or 
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less than wild-type activity, with the mutation at L804 producing activity close to 
background levels. Mutation of other residues, such as F799, E801, N806, and T809, 
showed 50% or less of wild-type activity. In contrast, mutations of residues S798 and 
D802 revealed no major differences from wild-type levels (fusion activity of >70%). 
 
Figure 2.4. Quantitative assays of membrane fusion mediated by mutant spike 
proteins.  
BHK cells were cotransfected with plasmids encoding wild-type (WT) SARS-CoV S 
or alanine mutants and also with luciferase cDNA under the control of a T7 promoter. 
At 24 h posttransfection, BHK cells were then overlaid with Vero cells previously 
transfected with a plasmid encoding T7 polymerase. After 3 h, fusion was induced 
using medium containing 2 µg/ml trypsin. The cells were lysed 6 h postfusion 
induction, and supernatants were measured for luciferase activity. Each bar is 
averaged from three individual experiments, and error bars represent standard 
deviations from the means. 
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Effects of SARS-CoV S fusion peptide mutants in MLV pseudotyped virions. To 
better understand the roles of these fusion peptide residues in the context of a virus 
particle, we employed a retrovirus-based pseudovirion system (1). Based on the cell-
cell fusion assays described above, we selected the core conserved residues identified 
as being critical to the fusion process as candidates for SARS-CoV S-expressing 
pseudoviral particles. In this infectivity assay, 293T cells were first cotransfected with 
an MLV Gag-Pol and luciferase plasmid along with either the SARS-CoV wild-type or 
mutant S protein plasmid or with an empty vector control to generate SARS-CoV S or 
control pseudotyped viral particles. The transfected cells were then incubated for 72 h 
at 32°C as this temperature was optimal for surface expression of the mutants. We first 
confirmed that a suitable level of expression of mutant spike protein was incorporated 
in the viral particles, in comparison to wild type, by blotting for spike protein in the 
collected supernatant 72 h posttransfection (Fig. 2.5A). With many of the mutants 
expressing at levels greater than 60% of the wild type, we observed a relative lack of 
spike protein incorporation in the S798A, I800A, E801A, L803A, and L804A mutants. 
The level of cell surface expression in 293T cells was also confirmed by our 
biotinylation assay (data not shown). In order to counter this lack of incorporation, we 
generated additional point mutants with the goal of identifying mutations that would 
allow efficient incorporation into pseudoparticles. We generated the following 
mutations: S798G, S798L, S798H, I800G, I800S, E801L, L803E, L803T, L804E, and 
L804T. All of these mutants were tested for the level of surface expression and 
incorporation into pseudotyped viral particles; however, only L803E and L804T (Fig. 
2.5B) showed incorporation above 60% in comparison to the wild type. 
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Figure 2.5. Incorporation of mutant spike proteins into MLV pseudotyped 
virions.  
Spike protein-MLV pseudotyped virions were prepared as described in Materials and 
Methods. Virions were concentrated using a 10% PEG precipitation, diluted in SDS 
sample buffer, and resolved by SDS-PAGE and Western blotting using a monoclonal 
antibody specific for the C9 tag. The spike protein-MLV pseudotyped virions were 
generated three times for wild type (WT) or mutants, and the results from the Western 
blotting were quantified using IP Lab software and plotted in Sigma Plot, version 9.0. 
Error bars represent standard deviations from the means. 
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Upon confirmation of mutant spike protein incorporation, Vero E6 cells were then 
transduced with SARS-CoV S pseudovirions, ensuring that equal amounts of viral 
particles were used in the infectivity assay by adjusting the volume of the supernatant. 
At 72 h posttransduction, cells were lysed, and luciferase activity was measured as an 
indicator of the extent of viral infection. The luciferase activity of the wild type was 
normalized to 100%, and luciferase activities of the mutants were compared to those of 
the wild type. As shown in Fig. 2.6A, we observed a distinct pattern that was similar to 
the quantitative cell-cell fusion data (Fig.2.4). A marked reduction in infectivity in the 
core of the proposed fusion peptide, especially in mutants L803E, L804T, F805A, 
V808A, and L810A, was observed in the pseudovirus infectivity assay. We also 
observed that the mutation of residues flanking the core, such as F799A, K807A, 
G814A, and F815A, have less effect in virus entry assays than suggested by the 
corresponding cell-cell fusion data.  
It is considered that SARS-CoV has the ability to fuse in both endocytic and 
nonendocytic compartments, and so we assessed any potential differences in the role 
of the proposed fusion peptide in each of these two pathways of virus entry. We 
therefore inhibited infection by the endocytic route using the lysosomotropic base 
NH4Cl and induced fusion of surface-bound virions by trypsin activation. At 48 h after 
trypsin treatment, cells were assayed for luciferase activity. We observed that, with the 
exception of G814 and F815, almost all the residues highlighted in the trypsin-
untreated assay as being important for infection were also critical in this assay of 
nonendosomal infection (Fig.2.6B).  
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Figure 2.6. Infectivity of spike protein-MLV pseudotyped virions.  
(A) Endosomal infectivity of spike protein-MLV pseudotyped virions. (B) 
Trypsin-mediated infectivity of spike protein-MLV pseudotyped virions. Each bar is 
averaged from three individual infectivity assays, and error bars represent standard 
deviations of the means. WT, wild type. 
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These residues show responses that vary from about 50% for F799A down to almost 
background levels, as observed in L803E. Data for cell-cell fusion and pseudovirus 
assays are summarized in Fig. 2.7. 
 
Figure 2.7. Summary of effects of S2 mutations on SARS-CoV S fusion activity.  
The fusion activity of SARS-CoV S wild-type (WT) and mutants in cell-cell fusion 
assays, as well as in pseudovirus assays of endosomal (– trypsin) and nonendosomal 
(+ trypsin) infection are summarized. +++, 80 to 100% of wild-type level; ++, 79 to 
50% of wild-type level; +, 49 to 20% of wild-type level; and –, <20% of wild-type 
level. ND, not determined. 
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Isolated peptides corresponding to the proposed SARS-CoV S2 fusion peptide 
promote lipid mixing. In order to determine the ability of our proposed fusion peptide 
to mediate membrane fusion, we utilized a FRET-based assay of lipid mixing (32). In 
this assay, if a peptide is able to mediate lipid mixing, labeled and unlabeled liposomes 
fuse, resulting in a dilution of FRET pairs present in the labeled liposomes and an 
increase in fluorescence of the donor chromophore. The extent of lipid mixing 
mediated by the SARS S2 peptide (SFIEDLLFNKVTLADAGFMKQYGCGKKKK) 
and a negative control are shown in Fig.2.8A. Lipid mixing was investigated at several 
concentrations of peptide, as well as at both pH 5 and pH 7. The SARS-CoV S2 
peptide promoted a greater extent of lipid mixing at a lower pH. At higher 
concentrations of peptide, lipid mixing was also evident at pH 7. The negative control 
peptide showed no lipid mixing at any concentration or pH tested. The extent of lipid 
mixing of the SARS-CoV S2 peptide as a function of pH is shown in Fig. 2.8B. We 
also tested a shorter version of the peptide (SFIEDLLFGCGKKKK), which also 
showed efficient lipid mixing (Fig. 2.8C and D). The short peptide was also somewhat 
dependent on pH, but the effects of low pH were less pronounced than with the longer 
peptide. To examine the function of SARS-CoV S residues L803, L804, and F805 in 
the context of isolated peptides, we tested a modified short peptide 
(SFIEDAAAGCGKKKK). In contrast to wild-type sequence, the modified LLF-AAA 
peptide showed no ability to induce lipid mixing. 
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Figure 2.8. The proposed SARS-CoV S2 fusion peptide induces lipid mixing in 
liposomes.  
(A) Extent of lipid mixing was determined by varying the ratios of  the fusion 
peptide or control peptide concentrations with the total concentration of labeled and 
unlabeled liposomes at pH 5 and pH 7. (B) Effect of the fusion peptide on lipid mixing 
at various pH values. The kinetics of lipid mixing was followed by monitoring 
fluorescence intensity at 530 nm upon addition of peptide for A or in decreasing-pH 
environments (from pH 7.0 to pH 4.5) for B. (C) Extent of lipid mixing at pH 7 and 
pH  5 (D) were determined by varying the ratios of wild-type or modified LLF-AAA 
fusion peptide with liposomes at various ratios of peptide to lipid. Each data point is 
averaged from three individual assays, and error bars represent standard deviations of 
the means. 
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CD spectroscopy indicates that the proposed SARS-CoV S2 fusion peptide has a 
helical secondary structure.  
With fusion peptides of many other class I fusion proteins, e.g., influenza virus HA, 
characterized to be predominantly alpha-helical in secondary structure, we were 
interested in the structure of the SARS-CoV S2 peptide and used CD spectroscopy as a 
way to resolve its secondary-structure content (Fig.2.9). The structure of the synthetic 
peptide SFIEDLLFNKVTLADAGFMKQYGCGKKKK was resolved in the presence 
and absence of TFE. TFE is a solvent used in many CD spectroscopy studies and 
functions to stabilize only structures that have the propensity to be helical (12). In the 
presence of TFE, the S2 fusion peptide gave a spectrum consistent with its having 
alpha-helical content; this was quantified to be approximately 37% alpha-helix. In the 
absence of TFE, the peptide maintained a structure in close resemblance to a random 
coil (Fig. 2.9A). A control peptide sequence downstream of the proposed S2 fusion 
peptide (residues 1021 to 1034) was used as a control. We also observed a major 
difference in the spectra of the proposed S2 fusion peptide compared to the control 
peptide, which maintained a structure closely resembling a random coil even in the 
presence of TFE (Fig. 2.9B). We also examined the structure of the shorter peptide 
SFIEDLLF. In the presence of TFE, the short S2 peptide also gave a spectrum 
consistent with its having a high degree of alpha-helical content, which was quantified 
to be approximately 77% alpha-helix (Fig. 2.9C).  
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 Figure 2.9. The proposed SARS-CoV S2 fusion peptide has the propensity to 
form helical secondary structure.  
(A) CD spectrum of the fusion peptide (solid line) in a TFE/fusion buffer ratio of 50% 
(vol/vol) at 37°C or in fusion buffer alone (dotted line). (B) CD spectrum of the fusion 
peptide (FP; solid line) alongside a control peptide (dotted line) in a TFE/fusion buffer 
ratio of 50% (vol/vol) at 37°C. (C) CD spectrum  of the short fusion peptide (solid 
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line) in a TFE/fusion buffer ratio of 50% (vol/vol) at 37°C or in fusion buffer alone at 
either pH 5.0 (dotted line) or pH 7.0 (dashed line). deg, degree. 
Discussion 
A common property of class I fusion proteins is that a proteolytic priming event is 
necessary for subsequent fusion activation that occurs following exposure to low pH 
and/or receptor binding. Proteolytic priming is classically associated with members of 
the trypsin or furin families (21), but more recently cathepsin family members have 
also been shown to prime fusion activation (38). In canonical class I fusion proteins, 
such as influenza virus HA or human immunodeficiency virus type 1 Env, proteolytic 
cleavage occurs directly N-terminal to the fusion peptide, in which case this is referred 
to as an "external," N-terminal fusion peptide (23, 38). In other cases, notably 
infection with avian leukosis sarcoma virus (ASLV) or EBOV, proteolytic priming still 
occurs with the cleavage site close to, but upstream from, the fusion peptide—in which 
case this is referred to as an "internal" fusion peptide (23, 38). Internal fusion peptides 
are generally considered to be relatively long (25 to 30 amino acids) and comprise an 
extended alpha-helix in the fusion-active state. In contrast, external class I fusion 
peptides are shorter (approximately 15 amino acids) and tend to have a helix-turn-helix 
structure, often with a central proline residue(s). In the case of CoV S proteins, 
proteolytic cleavage between the S1 and S2 domain often occurs, but there are no 
indications that this cleavage results in the exposure of a fusion peptide (4). Therefore, 
the S protein is generally considered to be a class I fusion protein with an internal 
fusion peptide.  
Recently, it has become apparent that cleavage at a second position (R797) also occurs 
in the SARS-CoV protein (2, 36), and we hypothesized that this second cleavage event 
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might expose a critical fusion peptide for the S protein. The sequence immediately C-
terminal to the R797 cleavage site of SARS-CoV S is SFIEDLLFNKVTLADAGF, 
and we assessed this peptide as a potential viral fusion peptide. The first factor we 
considered with regard to the potential of this peptide as a bona fide fusion peptide 
was the degree of conservation across the Coronaviridae. As shown in Fig.2.1, the 
peptide was extremely well conserved across all CoVs. In particular, the IEDLLF 
motif showed only minimal divergence, with occasional conservative substitutions (L 
to V and L to I). As viral fusion peptides are known to be highly conserved within a 
family (26), this gave us confidence to proceed with a comprehensive mutagenesis 
study of the putative fusion peptide, with fusion ability monitored by a cell-cell fusion 
assay. We initially took a conservative approach and carried out a replacement of 
individual amino acids with alanine residues. In all cases, mutations had limited or no 
effect on S protein assembly and cell surface expression; however, we saw marked 
effects on the ability to cause cell-cell fusion. In particular the L803A, L804A, and 
F805A substitutions had major effects on fusion, with fusion of the L804A mutant 
being undetectable in a highly sensitive luciferase-based fusion assay. Other residues 
with major effects on fusion (20% or less of wild-type levels) were K807A, D812A, 
and F815A. Notably, mutation of the new N terminus produced after cleavage at R797 
(S798A) had very little effect on cell-cell fusion. To date, mutations to more 
hydrophilic residues, which may have more dramatic effects on fusion, have not been 
carried out for most of the residues within the S2 fusion peptide.  
To confirm these results in the context of a virus particle, we created MLV 
pseudovirions containing wild-type and mutant SARS-CoV S proteins. In some cases, 
particularly for the apparently fusion-critical L803 and L804 residues, alanine 
substitutions could not be rescued in pseudovirus particles. In these cases, we made 
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additional substitutions, with the L803E and L803T mutations allowing efficient 
incorporation. The reasons for the differences in particle incorporation are currently 
unclear as both L803A and L804A showed nearly normal levels of cell surface 
expression. Pseudoparticle transduction was determined following both endosomal and 
nonendosomal routes, and in both cases results were essentially in line with cell-cell 
fusion data; i.e., fusion-critical residues (<20% of the wild-type level) were L803, 
L804, and F805, along with D812. The K807 and F815 residues seemed less critical in 
virus entry assays. Mutations at S798 failed to be incorporated into virus particles, and 
so the role of this residue could not be determined in this assay. Overall, these 
experiments appeared to point to L803, L804, and F805 as a fusion-active core of the 
proposed fusion peptide, with the N-terminal S798 residue being of only limited 
importance.  
To examine the fusion peptide more biochemically, we carried out lipid-mixing and 
spectroscopy assays. We initially assessed a long version of the peptide 
(SFIEDLLFNKVTLADAGF), but due to the apparent importance of the more N-
terminal hydrophobic resides (L803, L804, and F805), we also examined a short 
version of the peptide (SFIEDLLF) in lipid-mixing assays. By spectroscopy, the long 
and short peptides did not show any intrinsic structure but showed significant alpha-
helical content in the presence of TFE. We were not able to assess the structure in the 
presence of liposomes due to fusion and aggregation of liposomes when peptide was 
added. In both cases, lipid-mixing experiments showed that the peptides were fusion 
active; both peptides were more active at pH 5 than at pH 7.  
Notably, L803, L804, and F805 are the initial residues of a major antigenic 
determinant of SARS-CoV S (Leu 803-Ala 828) that is capable of inducing 
neutralizing antibodies (40). This SARS-CoV epitope is also homologous to an 
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immunodominant neutralizing domain on the MHV S2 subunit (7). It will be 
interesting to see if these neutralizing antibodies mediate their effects during 
membrane fusion, as found for the closely located 5B19 epitope of MHV S (33).  
While a crystal structure of the SARS-CoV S ectodomain has not yet been solved, a 
predictive model of the quaternary structure is available (Protein Data Bank code 
1T7G) (3). In the context of this model, the novel S2 fusion peptide is mainly helical 
(especially the conserved residues SXIEDLLF), with a short central unstructured 
region, and is in a relatively exposed position midway down the trimeric spike protein 
complex (Fig.2.10). This structure and position within the S trimer are consistent with 
its function as a viral fusion protein. In our initial bioinformatics analysis of the 
predicted SARS-CoV S fusion peptide, we were initially surprised by the presence of 
Figure 2.10. Structural model of the SARS-CoV S2. 
(A) A three-dimensional model of the SARS-CoV S protein ectodomain trimer is 
shown in cartoon form with the proposed fusion peptide shown in white and the 
S2 cleavage site (R797) shown in magenta. (B) The side chains of the proposed 
fusion-active core (L803, L804, and F805) are shown in enlarged form. 
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several charged residues, i.e., E801, D802, K807, and D812. While fusion peptides 
from pH-dependent viruses, such influenza virus, often contain negatively charged 
residues, the presence of positively charged residues is unusual. The three-dimensional 
structure of the proposed S2 fusion peptide (SFIEDLLFNKVTLADAGF) in this 
model predicts two short helices separated by a short unstructured region. While there 
is no obvious proline-containing turn motif (as in ASLV or EBOV), we consider that 
the SARS-CoV S2 fusion peptide does not follow the N-terminal alpha-helix pattern of 
influenza virus or human immunodeficiency virus type 1 but, rather, comprises an 
internal fusion peptide more like that of ASLV or Ebola virus, which is exposed by a 
proximal cleavage event. The major difference for SARS-CoV S would be that the 
known S2 cleavage site is closer to the core residues of the proposed fusion peptide (6 
to 8 amino acids away) rather than the 20 to 30 amino acids found for ASLV or EBOV 
(24, 27, 35, 38). 
It is also possible that alternative cleavage sites within the S2 domain could result in 
exposure of the fusion peptide. In this scenario, the charged residues of the proposed 
SARS-CoV S fusion peptide (E801, D802, K807, and D812) would lie outside the 
membrane-penetrating region and would be cytosolic or interact with the 
phospholipid head groups. In terms of structure, the membrane-penetrating, fusion-
active core of the SARS-CoV S2 fusion peptide would comprise residues L803, L804, 
and F805 and may be composed of a hydrophobic pocket in conjunction with a short 
310-helix, as proposed for EBOV (10, 24) and for influenza virus at low pH (18), 
although this will need to be addressed experimentally.  
The data presented here suggest the presence of a critical fusion peptide close to the S2 
cleavage site; however, in the absence of a crystal structure of SARS-CoV S in both 
pre- and postfusion forms, as well as more biophysical measurements of peptide 
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intercalation into membranes in the context of the complete S protein, we do not have 
formal proof that the region SFIEDLLFNKVTLADAGF constitutes the only fusion 
peptide for SARS-CoV S. It is possible that the fusion peptide identified here 
functions in conjunction with other fusion peptides or membrane-intercalating regions 
of the spike protein identified in previous work.  
While the low endosomal pH is important for SARS-CoV entry, other nonendosomal 
entry routes can occur. Thus, it is presently unclear whether low pH is needed only for 
activation of cathepsins priming the SARS-CoV S protein or whether low pH has a 
more direct role. Overall, however, it seems likely that CoVs in general can mediate 
membrane fusion at a range of pH values. The fusion peptide characterized here is 
highly conserved across the Coronaviridae, especially in the core IEDLLF sequence. 
It seems likely that this sequence, working in conjunction with other membrane-active 
regions of the spike protein, is an important feature of this diverse virus family at 
various pH values and with different cleavage events that could result in fusion peptide 
exposure.  
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Abstract 
 The S2 domain of the coronavirus spike (S) protein is known to be responsible for 
mediating membrane fusion. In addition to a well-recognized cleavage site at the S1-
S2 boundary, a second proteolytic cleavage site has been identified in the severe acute 
respiratory syndrome coronavirus (SARS-CoV) S2 domain (R797). C-terminal to this 
S2 cleavage site is a conserved region flanked by cysteine residues C822 and C833. 
Here, we investigated the importance of this well conserved region for SARS-CoV S-
mediated fusion activation. We show that the residues between C822-C833 are well 
conserved across all coronaviruses. Mutagenic analysis of SARS-CoV S, combined 
with cell–cell fusion and pseudotyped virion infectivity assays, showed a critical role 
for the core-conserved residues C822, D830, L831, and C833. Based on available 
predictive models, we propose that the conserved domain flanked by cysteines 822 
and 833 forms a loop structure that interacts with components of the SARS-CoV S 
trimer to control the activation of membrane fusion. 
Introduction 
The severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in 
2002 causing a global epidemic. The outbreak resulted in about 8,000 cases with a 
fatality of about 10% until it was quarantined (11, 14). SARS-CoV still maintains a 
significant threat to human health, as novel viruses such as these still present a 
possibility for re-emergence into the human population so an understanding of the 
mechanics of entry is crucial in order to develop effective treatment.  
Coronaviruses are enveloped viruses with positive sense RNA genomes that 
commonly cause respiratory and enteric diseases within a wide host range (18). Entry 
of these viruses is mediated by the viral spike glycoprotein S and a receptor on the 
target cell. The viral spike glycoprotein can be cleaved into S1 and S2 domains (3, 12, 
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13, 19-21, 39, 42). The S1 domain of the viral spike protein dictates tropism and is 
responsible for mediating receptor binding (7, 15-17, 23-25, 34, 38, 40). The S2 
domain is responsible for mediating membrane fusion between the virus and host cell, 
with strong sequence conservation within the family (5, 8)—hence the mechanics of 
fusion can be expected to be conserved across the Coronaviridae.  
Based on structural similarities, the SARS-CoV S glycoprotein is a class 1 
membrane fusion protein (33). The S2 domain contains two heptad repeat (14) 
regions, HR1 and HR2, as well as a fusion peptide. Following conformational changes 
based on receptor binding or change in pH, the S2 domain drives fusion of the viral 
and host cell membranes to allow virus entry. Observations of cell surface expressed 
SARS-CoV spike protein, indicated that most of the protein was not cleaved at the S1-
S2 boundary, at best limited cleavage is possible (35, 41). It is generally considered 
that S1-S2 cleavage is not directly linked to fusion peptide exposure in the case of 
SARS-CoV, or any other coronavirus (6). However, it has recently been shown that 
SARS-CoV S can be proteolytically cleaved at a downstream position in S2, at residue 
797 (2), and a highly conserved region C-terminal to the cleavage site has been 
characterized and identified as critical for fusion (26).  
Downstream of these conserved core residues we observed another set of 
conserved residues flanked by cysteines 822 and 833. These flanks represent two of 
the 39 cysteines in S that are likely to form intra-disulfide bonds within S. Cysteine 
residues and their roles in mediating entry either in the receptor binding region or in 
the cytoplasmic tail have been well documented for coronaviruses (30, 31, 37, 43). For 
other families of viruses, cysteine residues have been key players for driving entry (27, 
28) and fusion (9, 10, 29, 32) . In this study, we investigated the importance of a 
conserved domain in S2 flanked by cysteines 822 and 833 by carrying out a 
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comprehensive mutagenesis study. Using cell-cell fusion and pseudovirus assays, we 
show that this domain is critical for the activation of SARS-CoV S-mediated 
membrane fusion and virus entry. 
Results 
Bioinformatic analysis of the SARS-CoV S2 domain flanked by cysteine residues 
C822 and C833. 
A common feature of regions within a viral glycoprotein that is required for entry is 
that they show a high degree of conservation within a virus family. We therefore 
performed a multiple sequence alignment of the spike protein of representative 
coronaviruses, with a focus on the domain flanked by cysteine residues C822 and 
C833. This bioinformatic analysis confirmed a high degree of conservation in the 
region (Fig. 3.1). Indeed, residues C822, D830, L831, and C833 of the SARS-CoV S 
represent some of the most conserved residues in that region and across the 
Coronaviridae. 
Cloning and expression of WT and mutant SARS-CoV S glycoproteins. 
To test the fusogenic properties of the conserved S2 domain flanked by cysteine 
residues C822 and C833, point, double, deletion and insertion mutants were 
introduced into a SARS-CoV S protein-expressing vector to generate the following 
mutants: C822S, G824A, D825A, N827A, A828S, D830L, L831D, C833S, double 
cysteine mutant (C822S/ C833S), a deletion of the residues between the cysteines 
(Δ823-832) and a Gly-Ala-Gly (GAG) loop mutant to replace the residues between the 
cysteines. The rationale for the mutants was as follows: residues G824, D825, N827, 
and A828 were mutated to alanine (or serine in the case of A828) to modify their 
chemical nature in an innocuous manner. The conserved residue C822 and C833 were 
mutated to serines to change the chemical nature of the cysteines and prevent normal 
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disulfide bond formation; the C822S/C833S double mutant was designed to curb the 
possibility of spurious disulfide bonding occurring with unpaired cysteines; D830L, 
and L831D mutants were also generated to modify the chemistry of each original 
residue with the corresponding conserved residue, as both are 100% conserved; and to 
further address how residues within the proposed loop might be important, we 
generated a loop deletion mutant Δ823-832, and a flexible tripeptide GAG loop (22) 
between the flanking cysteines.  
 
 
Figure 3.1. Schematic and alignment of the cysteine flanked region 
 A schematic representation of the coronavirus spike with hallmark domains alongside 
the region of interest. A multiple sequence alignment of the S protein from 
representative coronavirus groups was performed. Residues that are conserved directly 
or in terms of properties are underlined and asterisked residues represent 100% 
conservation within the CoV family.  
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In order to evaluate the effect of the mutations on the fusogenic properties of SARS-
CoV S protein, we first verified the cell surface expression of the mutants. The level of 
surface expression of the point mutants was verified quantitatively after transfection of 
expression vectors bearing mutant or wild type S protein in BHK-21 cells, at both 
37°C and 32°C, followed by biotinylation and immunoblotting. At 37°C, with the 
exception of the N827A mutant, we observed a tolerable surface expression of many 
of the mutants (Fig. 3.2A), but at 32°C we observed an overall better surface 
expression of all mutants expressing at > 65% of wild-type levels (Fig. 3.2B) so this 
temperature was used in the corresponding surface expression fusion assays as well as 
in the generation of pseudotyped virions.  
Figure 3.2. Effect of point mutants on spike protein surface expression 
BHK cells were transfected with plasmids encoding wild type SARS-CoV S or 
mutants at (A) 37°C and (B) 32°C. The cells were labeled with biotin, proteins were 
affinity purified with NeutraAvidin beads and resolved by SDS-PAGE and analyzed 
by Western blot using anti C9 tag antibody. The biotinylation assay was repeated three 
times and the results plotted. The Error bars represent standard deviation of the mean. 
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Binding of soluble hACE2-Fc to wild type or mutant SARS-CoV S. 
With point mutants introduced into the viral glycoprotein, it was important to confirm 
that the binding to ACE2 the SARS-CoV receptor is not altered. To confirm this, we 
cotransfected 293T cells with a construct expressing human ACE2 fused to the Fc-
domain of human IgG (hACE2-Fc) and wild type or mutant spike vectors. 48 h post 
transfection, cells were lysed and affinity purified for hACE2-Fc, and then 
immunoblotted for SARS-CoV S to confirm interactions between receptor and spike. 
The levels of binding were observed to be comparable with mutants binding ACE2 at 
an average > 70% of wild type levels (Fig. 3.3).  
Figure 3.3. Effect of point mutants on receptor binding 
293-T cells were co-transfected with plasmids expressing wild type or mutant spike 
protein and human ACE2-Fc.The lysates were affinity purified using immobilized 
Protein A beads. Protein A beads were then washed and resolved via SDS-PAGE and 
Western blot. The binding assay was repeated three times and results from the western 
blot quantifications were plotted. 
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Fusion assays of cells expressing WT or mutant SARS-CoV S and ACE2. 
With a tolerable level expression at the cell surface verified, we were then able to 
evaluate how the mutations might affect membrane fusion. Taking advantage of 
trypsin as a fusion trigger for the spike protein, we employed a quantitative method of 
determining SARS-CoV S protein-mediated membrane fusion activity, by using a 
luciferase-based assay system to measure cell–cell fusion. In this assay, BHK-21 cells 
were cotransfected with wild type or mutant spike protein along with T7 polymerase-
driven luciferase gene and overlayed with Vero E6 cells transfected with the T7 
polymerase gene. Fusion was induced by trypsin treatment, and the degree of 
luciferase activity after induction of fusion was used as an indicator of the fusogenic 
ability of the mutant SARS-CoV S protein, in comparison to wild type (Fig. 3.4). 
 We observed that while alanine substitution of less conserved residues G824A, 
D825A, N827A, and A828S, displayed activity close to or better than wild type, 
mutation of the core conserved residues, as well as the loop deletion and mini-loop 
mutants resulted in luciferase activity that was close to background levels in 
comparison to wild type activity. 
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Figure 3.4. Quantitative assays of membrane fusion mediated by mutant spike 
proteins 
BHK cells were cotransfected with plasmids encoding wild type SARS-CoV S or 
alanine mutants and also with luciferase cDNA under the control of a T7 promoter. At 
24 h post transfection, BHK cells were then overlaid with Vero cells previously 
transfected with a plasmid encoding T7 polymerase. After 3 h, fusion was induced 
using media containing 2 µg/ml trypsin. The cells were lysed 6 h post fusion induction 
and supernatants measured for luciferase activity. Each bar is averaged from three 
individual repeats and error bars represent standard deviation from the mean. 
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Characterization of SARS-CoV S mutants in MLV-pseudotyped virions. 
To better understand the roles of S2 domain flanked by cysteine residues C822 and 
C833 in the context of a virus particle, we employed a retrovirus-based pseudovirion 
system (1). In this infectivity assay, 293T cells are first cotransfected with a murine 
leukemia virus (MLV) Gag-Pol and luciferase plasmid along with either the SARS-
CoV wild type or mutant S protein plasmid, or an empty vector control, to generate 
control-pseudotyped viral particles missing the SARS-CoV S. The transfected cells 
were then incubated for 72 h at 32°C, as this temperature was optimal for surface 
expression of the mutants. We first confirmed that a suitable level of expression of 
mutant spike protein was incorporated in the viral particles, in comparison to wild 
type, by blotting for spike protein in the collected supernatant 72 h post transfection 
(Fig. 3.5).  
Although mutant N827A showed a low level of spike incorporation, the other mutants 
expressing at levels greater than 60% of the wild type the level of cell surface 
expression in 293T was also confirmed by our biotinylation assay (data not shown). 
Upon confirmation of mutant spike protein incorporation, Vero E6 cells were then 
transduced with SARS-CoV S pseudovirions with comparable levels of detected spike 
by adjusting the volume of the supernatant to ensure that equal amounts of S protein 
were used in the infectivity assay. At 72 h post transduction, cells were lysed and 
luciferase activity measured as an indicator of the extent of viral infection. The 
luciferase activity of the wild type construct was set to 100% and luciferase activities 
of the mutants were normalized to wild type.  As shown in Fig. 3.6A, we observed a 
pattern that was similar to the quantitative cell–cell fusion data (see Fig. 3.4) although 
the level activity of the D825A mutant is at an average of about 70% of the WT.  
 
  77 
 
Figure 3.5. Incorporation of mutant spike proteins into MLV pseudotyped 
virions 
Spike protein-MLV pseudotyped virions were prepared as described in the methods. 
Virions were concentrated using a 10% PEG precipitation, diluted in SDS sample 
buffer, and resolved by SDS-PAGE and Western blot using a monoclonal antibody 
specific for the C9 tag. The spike protein-MLV pseudotyped virions were generated 
three times for wild type or mutants, and the results from the Western blots were 
quantified using IP lab software and plotted in Sigma Plot 9.0. Error bars represent 
standard deviation from the mean.  
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It is considered that SARS-CoV has the ability to fuse in both endocytic and non-
endocytic compartments, and as such we assessed any potential differences in the role 
of this cysteine-flanked region in each of these two pathways of virus entry. We 
therefore inhibited infection by the endocytic route using the lysosomotropic base 
NH4Cl, and induced fusion of surface-bound virions by trypsin activation. At 48 h 
post trypsin-treatment, cells were assayed for luciferase activity. We observed that in 
this assay of non-endosomal infection that the overall results reflect both trypsin-
untreated assay and the cell-cell fusion data (Fig. 3.6B).  
Discussion 
The coronavirus spike protein is responsible for mediating both the attachment and 
fusion that is required to deliver the viral genome. Binding of the virus to the host cell 
receptor sets in motion a series of rearrangements of the fusion protein in preparation 
for fusion. The fusion event as directed by the S2 domain requires a concerted 
cooperation within the domains of the fusion protein. In this study, we describe 
another region essential to the S2 function of fusing host and viral membrane. 
It has been recently published that a critical cleavage event at R797 occurs in 
SARS-CoV S (2), which might expose a viral fusion peptide (26). 25 residues C-
terminal to the cleavage site, we observed an interesting conserved domain flanked by 
cysteine residues C822 and C833. Given its proximity to a cleavage site and the 
proposed fusion peptide, we set out to characterize this domain. Sequence alignment 
of this domain showed a strong conservation particularly in the C-terminus of the 
region. We set out to carry out a series of mutagenic studies in a comprehensive 
manner. Our investigation entailed the replacing of core-conserved residues with 
residues to modify the chemistry of the wild type, and substituting or deleting the 
residues between the cysteines. This comprehensive investigation of the residues  
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between C822 and C833 allowed us to gauge the extent of involvement of this region  
Figure 3.6. Infectivity of spike protein-MLV pseudotyped virions 
A. Endosomal infectivity of spike protein-MLV pseudotyped virions. Virions were 
bound to Vero cells at 4°C in RPMI media for 2hrs. After binding, cells were rinsed in 
RPMI media before replaced with complete DMEM and incubated at 37°C. 48 h post-
binding cells were lysed and assayed for luciferase activity. B. Trypsin-mediated 
infectivity of spike protein-MLV pseudotyped virions. Virions were bound to Vero 
cells at 4°C in RPMI media and treated with 25mM ammonium chloride. Fusion was 
induced using serum-free media containing 2 µg/ml trypsin. The cells were lysed 48 h 
post fusion induction and supernatants assayed for luciferase activity. Each bar is 
averaged from three individual infectivity assays and error bars represent standard 
deviation of the mean. 
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in the membrane fusion process. In all cases, we observed very limited to no effects on 
either surface expression or receptor binding, but observed drastic loss in fusogenic 
ability in the mutants of the core conserved residues, in comparison to the wild type 
SARS-CoV S in cell-cell fusion assays. 
In the context of a virus particle, we generated MLV-pseudovirions containing 
either WT or mutant S proteins. The mutant proteins were found to incorporate into 
MLV-pseudovirions at a level suitable for assessment of S function during virus entry. 
Upon pseudoparticle transduction, a drastic loss in the ability to infect cells was 
observed for both “endosomal” and “non-endosomal” routes of infection. The manner 
of sensitivity for these MLV-S mutants was very similar to the cell-cell fusion data 
thus indicating the importance of this region for fusion. 
We hypothesize that this region acts a means of relaying the signal for fusion 
within the subunit of S2, presumably based on comformational changes induced by 
low pH and /or receptor binding. One possible way the domain flanked by cysteine 
residues C822 and C833 may do so is by forming a disulfide bond-anchored loop that 
interacts with an as yet undisclosed part of the fusion protein to promote membrane 
fusion. In the absence of a crystal structure of the SARS-CoV S ectodomain, a 
predictive model of the quaternary structure is available: PDB code 1T7G (4, 36) (Fig. 
3.7A). In the context of this model, the cysteine-flanked region is represented as a loop 
region with the cysteines 822 and 833 positioned directly next to each other, which we 
predict to form a disulfide bond (Fig. 3.7B).  
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Figure 3.7. Predicted structural model of the Cysteine flanked region  
A. A three dimensional model of the SARS-CoV S protein ectodomain trimer with the 
cysteine-flanked region colored white, both the S1 and S2 cleavage sites (R667 and 
R797) colored red and HR1 in green.  
B. A monomer of the spike depicting the environment of the cysteine flanked region. 
The side chains of conserved residues C822, D830, L831 and C822 are shown. 
The environment is one that might hint at further interactions with other parts of the 
spike protein. Of particularly interest is the finding that residues C822, L823, G824, 
D825, I826, N827 and A828 within the loop are part of a major antigenic determinant 
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of SARS-CoV S (Leu 803 - Ala 828) capable of inducing neutralizing antibodies (44) . 
In conclusion, we present data of a critical domain of SARS-CoV S2 that is required 
for the successful function of S-mediated fusion. We propose this region functions by 
interactions with other domain(s) in S to activate membrane fusion. It is important to 
point out that in the absence of a “true” crystal structure, we cannot rule out the fact 
that this region may function through many other possible roles within SARS-CoV S 
to aid in membrane fusion. 
Materials and methods 
Cell culture 
BHK-21, Vero E6 and 293T cells obtained from the American Type Culture 
Collection were used in this study. All cells were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM, Cellgro) containing 10% fetal bovine serum, 100 units/ml 
penicillin and 10 µg/ml streptomycin (complete DMEM). 
Generation of mutant SARS-CoV spike glycoproteins 
Site-directed mutagenesis was carried out on the spike protein-expressing vector 
pcDNA3.1-SARS-CoV S (kindly provided by Dr. Michael Farzan, New England 
Primate Research Center) via PCR, using primers obtained from IDT technologies. 
Mutations were then confirmed by sequencing using an Applied Biosystems 
Automated 3730 DNA Analyzer at the Cornell University Life Sciences Core 
Laboratories Center. 
 
Analysis of SARS-CoV S cell surface expression 
BHK-21 cells were grown on 6 well plates and transfected with 1 µg of wild type or 
mutant spike protein expressing plasmids using Lipofectamine 2000 (Invitrogen) for 
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36 h at 32°C or 24 h at 37°C. Transfected cells were washed twice with cold 
phosphate buffered saline (PBS) and then labeled with 250 µg/ml Sulfo-NHS-SS-
biotin (Pierce) for 30 min on ice. 50 mM cold glycine solution was added to the cells 
three times at 5 min intervals to quench unlabelled free biotin followed by a PBS 
wash. The cells were lysed in 500 µl of lysis buffer (Tris-buffered saline (TBS) 
containing 1% NP-40 and complete protease inhibitor mixture (Roche Applied 
Science)). The lysates were affinity purified using immobilized NeutraAvidin beads 
(Pierce) overnight at 4°C. NeutraAvidin beads were then washed with lysis buffer 
followed by addition of SDS-PAGE sample loading buffer containing 100mM 
dithiothreitol. The surface expression was analyzed by Western blot using the anti-C9 
epitope tag monoclonal antibody Rho 1D4 (National Cell Culture Center, Minneapolis 
MN) and images were obtained and quantified using a LAS-3000 mini Fuji film 
imaging system and software (Fuji Photo Film Co., Ltd). The biotinylation assay was 
repeated three times and results from the western blot quantifications were plotted 
using Sigma Plot 9.0 (Systat Software). 
Human ACE2-Fc binding Assay 
293-T cells were grown on 6cm dishes and co-transfected with 2 µg each of wild type 
or mutant spike protein expressing plasmids and human ACE2-Fc expressing plasmids 
using Lipofectamine 2000 (Invitrogen) for 48 h at 32°C. Transfected cells were 
washed with cold phosphate buffered saline (PBS) and the cells were lysed in 500 µl 
of lysis buffer (Tris-buffered saline (TBS) containing 1% CHAPS and complete 
protease inhibitor mixture (Roche Applied Science)). The lysates were affinity 
purified using immobilized Protein A beads (Pierce) overnight at 4°C. Protein A beads 
were then washed three times with 0.5% CHAPS lysis buffer followed by addition of 
SDS-PAGE sample loading buffer containing 100mM dithiothreitol. The SARS CoV 
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S binding to precipitated ACE2-Fc was analyzed by Western blot using the anti-C9 
epitope tag monoclonal antibody Rho 1D4 (National Cell Culture Center, Minneapolis 
MN) and images were obtained and quantified using a LAS-3000 mini Fuji film 
imaging system and software (Fuji Photo Film Co., Ltd). The binding assay was 
repeated three times and results from the western blot quantifications were plotted 
using Sigma Plot 9.0 (Systat Software). 
Quantitative cell-cell fusion assay 
BHK-21 cells were grown in 24 well plates and co-transfected with wild type or 
mutant spike protein-expressing plasmids and a plasmid encoding luciferase under the 
control of a T7 promoter, using Lipofectamine 2000 (Invitrogen) for 24 h at 32°C. 
Vero E6 cells in a 60 mm dish were also transfected with a plasmid encoding the T7 
polymerase. After 24 h the BHK-21 cells were overlaid with Vero E6 cells and 
incubated for 3 h. Cells were treated with serum-free media containing 2 µg/ml trypsin 
to induce fusion and replaced with complete DMEM after 30mins. At 6 h post 
induction, cells were lysed and assayed for Luciferase activity using a Luciferase 
assay kit (Promega) and a Glomax 20/20 luminometer (Promega) to measure light 
emission. 
Spike protein-pseudotyped virion production 
Pseudotyped virions were generated using plasmids kindly provided by Dr. Jean 
Dubuisson  (Lille Pasteur Institute, France). 293T cells were cotransfected with a 
murine leukemia virus (MLV)-based transfer vector encoding luciferase, a MLV Gag-
Pol packaging construct and a pcDNA3.1-SARS-CoV S plasmid encoding wildtype or 
mutant spike envelope glycoprotein, using Exgen 500 (Fermentas) as recommended. 
After incubation for 72 h at 32°C, supernatants were collected and filtered through a 
0.45 µm pore size membrane. The level of spike protein incorporation was confirmed 
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by polyethylene glycol (PEG) concentration, centrifugation and western blot analysis. 
600 µl of filtered supernatant was mixed with 200 µl 40% PEG and centrifuged for 30 
min at 4000 rpm at 4°C. The pellet was redissolved in SDS-PAGE sample loading 
buffer containing 100 mM dithiothreitol and blotted in the same manner as described 
above in the cell surface biotinylation assay.  
Spike protein-pseudotyped virion infectivity assays 
Equal levels of pseudoparticles were used based on the level of spike protein-
pseudotyped virions quantified by Western blot, as described above. For a typical 
infection assay, spike protein-pseudotype virions containing wild-type or mutant 
glycoproteins were bound for 2 h in RPMI media containing 0.2% BSA, 20 mM 
HEPES to Vero E6 cells at 4°C. Media was exchanged for complete DMEM and 
incubated for 48 h at 37°C. The cells were then lysed and luciferase activity measured 
using the same methods as the quantitative cell-cell fusion assay. In a trypsin-mediated 
cell surface infectivity assay, Vero E6 cells were first pre-incubated with 25 mM 
NH4Cl for 1 h at 37°C. Pseudotyped virions were then bound for 2 h in RPMI media 
containing 0.2% BSA, 20mM HEPES, and 25 mM NH4Cl at 4°C. The cells were then 
warmed up with the addition of pre-warmed RPMI media containing 5 µg/ml trypsin, 
0.2% BSA, 20 mM HEPES, and 25 mM ammonium chloride for 5 min at 37°C in a 
water bath. 
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CHAPTER 4 
HEPARAN SULFATE IS A SELECTIVE ATTACHMENT FACTOR FOR THE 
AVIAN CORONAVIRUS IBV BEAUDETTE  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ikenna G. Madu, Victor C. Chu, Hwajin Lee, Andrew D. Regan, Beverley E. 
Bauman   and Gary R. Whittaker. 2007. Avian Diseases: Vol. 51, No. 1, pp.45-51. 
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Summary 
The avian coronavirus infectious bronchitis virus (IBV) strain Beaudette is an embryo-
adapted virus that has extended species tropism in cell culture. In order to understand 
the acquired tropism of the Beaudette strain, we compared the S protein sequences of 
several IBV strains. The Beaudette strain was found to contain a putative heparan 
sulfate (HS)-binding site, indicating that the Beaudette virus may use HS as a selective 
receptor. To ascertain the requirements of cell surface HS for Beaudette infectivity, we 
assayed for infectivity in the presence of soluble heparin as a competitor, and 
determined infectivity in mutant cell lines with no HS or glycosaminoglycan 
expression. Our results indicate that HS plays a role as an attachment factor for IBV, 
working in concert with other factors like sialic acid to mediate virus binding to cells, 
and may explain in part the extended tropism of IBV Beaudette. 
Introduction 
Coronaviruses show strong species and tissue tropism, and a major factor in this 
specificity is the virus receptor on host cells (19). The viral S protein mediates 
receptor binding, and has been studied in some detail for many coronaviruses, a 
principal exception being group 3 coronaviruses such as IBV. Group 1 coronaviruses 
(e.g., HCoV 229E, transmissible gastroenteritis virus, and feline infectious peritonitis 
virus) are well established to use aminopeptidase N (CD13) as a primary receptor 
(14,22,36,42); indeed most, if not all, members of this group can apparently use the 
feline aminopeptidase N (fAPN) for productive entry (35). An exception to this is the 
recently identified human coronavirus NL63, which uses angiotensin-converting 
enzyme 2 (ACE2), the severe acute respiratory syndrome (SARS)-CoV receptor (18). 
In the case of group 2 coronaviruses, glycoproteins in the carcinoembryonic antigen-
related glycoprotein family act as receptors (12,39) and SARS-CoV uses ACE2 likely 
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in combination with CD209L (20,25). There is one published report that fAPN may 
act as a receptor for the IBV strain Arkansas 99 (30); however, it is unclear whether 
APN is a general receptor for IBV. Recently, sialic acid has been identified as a 
receptor determinant for the IBV strains Massachusetts 41 and Beaudette-US (40). 
The coronavirus receptor is generally considered to be the primary determinant of host 
range, and this has recently been shown in some detail for SARS-CoV. Viruses 
isolated during the 2002–2003 SARS outbreak, during the much less severe 2003–
2004 outbreak, and from palm civets were analyzed. All three S proteins bound to and 
used palm civet ACE2 efficiently, but the latter two S proteins used human ACE2 
markedly less efficiently, and the lower affinity S proteins could be complemented by 
incorporating specific mutations (26). 
Like most coronaviruses, clinical isolates of IBV show distinct tropism both in vivo 
and in cell culture. The prototype IBV strain (Massachusetts 41 [M41]) causes an 
acute, highly contagious respiratory disease in chickens. The virus can also replicate in 
the gastrointestinal tract, oviduct, and kidney, where it can be highly 
nephropathogenic with the potential to cause up to 44% mortality (8,11); in some 
cases infection of the proventriculus leads to 75%–100% mortality in young birds 
(43). IBV is distributed worldwide, and in the United States several serotypes (e.g., 
Arkansas and Delaware) are currently circulating in addition to the originally 
identified Massachusetts type. Most isolates of IBV replicate well in the developing 
chicken embryo following inoculation of the allantoic cavity, and high titers of virus 
can be isolated from the allantoic fluid. The IBV strain Beaudette was derived from 
the prototypic M41 strain following at least 150 passages in chick embryos (2,16,29). 
IBV Beaudette is no longer pathogenic for adult birds but rapidly kills embryos. In 
terms of host cells, IBV M41 is normally restricted to infection of primary chicken 
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cells; however, the Beaudette strain of IBV is known to be able to infect a range of 
cells in culture, including Vero and baby hamster kidney (BHK) (1,17,31). IBV 
Beaudette therefore represents a significant virus that has extended its host range 
based on very limited changes in its S protein. IBV M41 and Beaudette are closely 
homologous (having 96% amino acid identity in their S proteins) and the replacement 
of the Beaudette S protein with that of M41 shows that the S protein (and by 
implication the receptor-binding properties of the virus) is the sole determinant of its 
extended species tropism (7). 
Here we carried out a bioinformatic analysis of the S protein of IBV M41 and 
Beaudette and identified a unique heparin-binding consensus sequence on the 
Beaudette S protein. We show that IBV Beaudette infection is specifically inhibited by 
soluble heparin and is restricted for infection in heparan sulfate (HS)-deficient cells, 
indicating that the specific use of heparan sulfate as an attachment factor is involved in 
the extended species tropism of IBV Beaudette, most likely in conjunction with sialic 
acid moieties as well as an additional specific, but unidentified, receptor protein used 
by all strains of IBV. 
Materials and Methods 
Virus Growth and Cell culture 
IBV (strains Beaudette 42 and Massachusetts 41) were obtained from Dr. Benjamin 
Lucio-Martinez, Unit of Avian Health Cornell University and propagated in 11 day-
old embryonated chicken eggs. Virus was harvested from the allantoic fluid after 24 h 
of infection for Beaudette and 48 h of infection for Massachusetts 41). BHK cells were 
obtained from ATCC and grown in DMEM containing 10% fetal calf serum. Wild 
type CHO cells, as well as the GAG-deficient mutants CHO-677 and CHO-745, were 
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obtained from ATCC and grown in alpha MEM containing 10% fetal calf serum. 
Heparin, sodium salt, was obtained from Sigma. Neuraminidase (from Vibrio cholera) 
was obtained from Roche Applied Science. 
Preparation of primary chick kidney (CK) and chick embryo kidney (CEK) cells 
For preparation of CK cells, SPF White Leghorn Chicks (11-14 days of age) were 
placed in a CO2 chamber and kidneys removed from each side of the chick. Kidney 
tissue was placed in 25-50 ml sterile PBS and the container shaken gently to remove 
clots and red blood cells. The supernatant containing the cells was removed and cells 
rinsed a second time with an equivalent volume of sterile PBS. 25 ml trypsin/EDTA 
was added and allowed to rinse/digest for approx. 2 min with a stir bar on a stir plate 
(or by hand-swirling). The trypsin/EDTA was decanted or aspirated and a further 10 
ml trypsin/EDTA added. This was then allowed to digest for 2 min with a stir bar on 
stir plate (or by hand-swirling). The supernatant was poured through sterile cheese-
cloth into a sterile beaker with 1 ml FBS on ice, and the trypsin/EDTA digest repeated 
1-2 more times until all chunks of tissue were digested. The supernatant was placed 
into a 50 ml Falcon tube and centrifuged at 1,000 r.p.m. for 2 min. Cells were 
resuspended in 25 ml M20 media and counted on a hemocytometer. Cells were 
adjusted to a concentration of 1-1.5 x106/ml with M25 media containing 5% FBS.  
Preparation of CEK cells was essentially as for CK cells, except that kidneys were 
removed from 19 day chick embryos. 
RT-PCR reaction and DNA sequencing 
vRNA was extracted from 0.2 mg of sucrose purified virus stock using an RNeasy 
Plus Mini kit (Qiagen). 10 ng of vRNA was subjected to RT-PCR reaction using the 
forward primer (5’-TGAAAACTGAACAAAAGACAG-3’) and reverse primer (5’-
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CTTGTATTAGTTGTTGGAGCG-3’) using a OneStep RT-PCR kit (Qiagen) 
according to manufacturer’s instructions. The full-length cDNA product of the IBV 
spike glycoprotein gene was then purified using QIAquick Gel Extraction kit (Qiagen) 
and sequenced by the Biotechnology Resource Center (Cornell University). Individual 
sequences were further analyzed and aligned using the ClustalW online software from 
the European Bioinformatics Institute (http://www.ebi.ac.uk/clustalw). 
Immunofluorescence microscopy  
This was essentially performed as described previously (34), except with methanol 
fixation for IBV antibodies. IBV was identified using anti-S1 monoclonal antibody 
15:88 (21).  Secondary antibodies used were Alexa 488-labeled or Alexa 568-labeled 
goat anti-mouse or chicken IgG (Molecular Probes). Nuclei were counterstained with 
7.5 mg/ml Hoechst 33258 (Molecular Probes). Cells were viewed on a Nikon Eclipse 
E600 fluorescence microscope and images captured with a Sensicam EM camera and 
IPLab software before transfer into Adobe Photoshop 7 and determination of infection 
frequency. 
Flow cytometry 
 For flow cytometry preparation, cells were scraped gently from the dish, washed in 
PBS, fixed in 3% paraformaldehyde/PBS, permeabilized in 0.1% Triton X-100 and 
blocked in 10% goat serum/PBS. To detect virus infection cells were incubated with 
the monoclonal antibody 15:88 for 30 min, followed by Alexa 488-labeled goat anti-
mouse IgG for 30 min. Cells were analyzed on a FACSCalibur cytometer using 
CellQuest 3.1f software (Becton Dickinson Immunocytometry Systems). Data analysis 
was performed with Flow Jo 4.6 software (Treestar Inc.). At least 104 cells were 
analyzed for each sample. 
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Results  
Whereas most strains of IBV have restricted tropism, and only efficiently infect 
embryonated eggs and primary chicken cells in tissue culture, IBV Beaudette has 
extended species tropism in cell culture. As a way to examine possible differences in 
tropism, we carried out a bioinformatics analysis of the spike protein sequences for 
these viruses, with the goal of identifying possible novel receptor-binding sites on the 
Beaudette virus. We first performed DNA sequence analysis of the Beaudette and 
prototype Massachusetts (M41) viruses used in our laboratory. The S gene from each 
virus was reverse-transcribed and then PCR amplified from purified virions, and 
sequenced. These sequences were designated Bddt_Cornell and Mass41_Cornell and 
showed a high degree of similarity to published Beaudette and M41 sequences. 
Sequence information for these viruses is available at NCBI (accession number 
DQ664534). The predicted amino acid sequences of Bddt_Cornell and 
Mass41_Cornell were then aligned with the S protein sequences from a number of 
other representative IBV strains (Fig. 4.1). We observed that IBV Beaudette encoded a 
novel sequence (SRRKRS or SRRRRS) between residues 686 and 691 that may 
comprise a heparin-binding site—having a consensus sequence of XBBXBX, where B 
is a basic residue and X is any amino acid (6). This consensus was present in all 
Beaudette sequences available in the database, but not present for any other IBV strain 
analyzed. Because of the known propensity of heparan sulphate (HS) to act as a viral 
co-receptor (28), we therefore investigated the possible role of the HS as a co-factor in 
the extended tropism of IBV Beaudette. We first examined whether IBV Beaudette 
infection could be competed by soluble exogenous heparin. BHK cells were infected 
with approximately 1 FFU/cell IBV Beaudette, and infection was analyzed at 8 h post 
infection by immunofluorescence microscopy using an anti-IBV S1 monoclonal 
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antibody. 
 
Figure 4.1. Sequence alignment of the region including the potential heparin-
binding site of IBV Beaudette.  
The single letter amino acid code is used. Asterisk indicates that the residues are 
identical in all sequences in the alignment, colon indicates that conserved substitutions 
are present relative to Bdtt_Cornell, period indicates that semiconserved substitutions 
are present relative to Bdtt_Cornell. The heparin-binding consensus sequence, 
XBBXBX, is indicated with a gray box, where B = a basic residue and X = any 
residue. Amino acid residue numbers based on the GenBank submissions are 
indicated.  
 
In the absence of soluble heparin, approximately 90% of the cells were infected, 
however in the presence of excess soluble heparin, infectivity was not detectable (Fig 
4.2A). To quantify the effect of soluble heparin, we carried out a dose-response 
experiment of IBV Beaudette infection in BHK cells by flow cytometry (Fig 4.2B). 
We found that whereas 15 mg/ml soluble heparin gave a complete inhibition of viral 
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infectivity, 12 mg/ml gave an approximately 50% block, and 8mg/ml or lower gave 
only a limited or undetectable inhibition of infection.  
 
Figure 4.2. Soluble heparin prevents infection by IBV Beaudette 
(A) BHK cells were infected with IBV Beaudette that had been treated with 15 
mg/ml heparin (c and d) or were untreated (a and b). Cells were analyzed at 8 hr after 
infection by immunofluorescence microscopy using an anti-S1 monoclonal antibody 
to detect IBV infection (b and d) and nuclei counterstained with Hoechst 33258. (B) 
BHK cells were infected with IBV Beaudette that had been treated with varying 
concentrations of heparin, or were untreated. Cells were also mock infected. Cells 
were analyzed at 8 hr after infection by flow cytometry using an anti-S1 monoclonal 
antibody.  
 
To confirm that the effects of the higher levels of soluble heparin were specific for 
virus entry, we repeated the experiments adding the heparin after the first 60 min of 
virus infection. Under these conditions, we observed no significant inhibition of IBV 
infection (data not shown).  
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To determine whether the effects of soluble heparin were specific for IBV Beaudette, 
we repeated the experiments in primary chicken kidney (CK) cells and compared the 
infectivity of IBV Beaudette with the prototype Massachusetts 41 (M41) strain. In the 
absence of soluble heparin, addition of approximately 1 FFU/cell IBV M41 gave 
approximately 60-70% infectivity of CK cells, a level of infection that was essentially 
unchanged incubation with excess soluble heparin (Fig. 4.3).  As with BHK cells, 
approximately 90% of the CK cells were infected by IBV Beaudette in the absence of 
excess soluble heparin, whereas infectivity of CK cells with IBV was not detectable 
after incubation with heparin (Fig 4.3). These data show a specific requirement of HS 
for infection by IBV Beaudette. 
Heparan sulphate (HS) is an abundant cell-surface glycosaminoglycan (GAG) that is 
widely used as a viral attachment factor (28), however other cell-surface GAGs are 
also expressed at high levels (notably chondroitin sulphate, CS) and can be used as 
viral receptor moieties (32). To assess the specific contribution of cell surface HS for 
infection by IBV Beaudette we utilized two mutant CHO cells lines; CHO-745, which 
is deficient in overall GAG biosynthesis due to a mutation in the xylotransferase I 
gene, and CHO-677, which is specifically deficient in HS biosynthesis due to 
mutations in the N-acetylglucosaminyl transferase and glucuronosyl transferase genes 
(15, 37).  
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Figure 4.3. Soluble heparin does not prevent infection by IBV M41 
Approximately 1 FFU/cell IBV Massachusetts 41 (M41) (a, b, e  and f) or  Beaudette 
(Bddte) (c, d, g  and h) was used to infect primary chick kidney (CK) cells that had 
been treated with 15mg/ml heparin (e-h)) or were untreated (a-d)). Cells were 
analyzed at 8 h post infection by immunofluorescence microscopy using an anti-S1 
monoclonal antibody to detect IBV infection (b, d, f and h)) and nuclei counterstained 
with Hoechst 33258 (a, c, e and g). 
We first examined CHO-677 cells, which express no detectable cell-surface HS, but 
have a three fold-higher expression of CS (15).  Infection of wild-type CHO cells with 
approximately 1 FFU/cell IBV Beaudette resulted in an approximately 70% of the 
cells being infected. However, infection of CHO-677 cells was significantly reduced 
or undetectable (<5% infection) (Fig 4.4), confirming the important role for HS in 
infection by IBV Beaudette.  
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Figure 4.4. IBV Beaudette does not infect heparan sulphate deficient cells 
Approximately 1 FFU/cell IBV Beaudette was used to infect CHO-677 cells (panels c 
and d) or wild type CHO cells (panels a and b). Cells were analyzed at 8 h post 
infection by immunofluorescence microscopy using an anti-S1 monoclonal antibody 
to detect IBV infection (panels b and d) and nuclei counterstained with Hoechst 33258 
(panels a and and c). B) Quantification of immunofluorescence data. > 300 cells were 
scored for infection. Error bars represent the standard deviation of the mean. 
 
 
We next examined CHO-745 cells, which have no detectable cell-surface GAG (15). 
Unexpectedly, these cells showed no significant reduction in the level of IBV 
Beaudette infection; for both wild-type and CHO-745 cells we observed 
approximately 70-75% infection (Fig 4.5). To account for the apparent discrepancy in 
the data from CHO-677 vs. CHO-745 cells, we considered the possibility that whereas 
elimination of specific HS-binding sites led to a reduction in IBV Beaudette infection 
by virtue of the fact that IBV Beaudette–HS interactions were prevented, elimination 
of all cell surface GAGs in CHO-745 cells exposed an alternative virus binding site(s) 
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which could act as a virus receptor.  
 
Figure 4.5. IBV Beaudette infects glycosaminoglycan-deficient cells 
A) Approximately 1 FFU/cell IBV Beaudette was used to infect CHO-745 cells (c and 
d) or wild type CHO cells (a and b). Cells were analyzed at 8 h post infection by 
immunofluorescence microscopy using an anti-S1 monoclonal antibody to detect IBV 
infection (b and d) B) Quantification of immunofluorescence data. > 300 cells were 
scored for infection. Error bars represent the standard deviation of the mean. 
 
As sialic acid residues have recently been shown to be involved in binding and entry 
of IBV (40), we reasoned that CHO-745 cells may have increased sialic acid binding 
capacity, which overcomes the lack of HS. We therefore assessed the effect of 
neuraminidase (NA) treatment on infection of CHO-745 cells, along with the effects 
of NA on CHO-677, wild type CHO and BHK cells.  Cells were infected with 
approximately 1 FFU/cell IBV Beaudette. In all cases treatment with NA reduced  
infection to a level <5% of that in the absence of NA (Fig. 4.6). Therefore, we 
consider that HS acts in conjunction with sialic acid for infection of cells by IBV 
  107 
Beaudette.  
 
Figure 4.6. Neuraminidase treatment prevents IBV Beaudette infection of 
glycosaminoglycan-deficient cells 
Approximately 1 FFU/cell IBV Beaudette was used to infect BHK (a, b, i and j), wild 
type CHO (c, d, k and l), CHO-677 (e, f, m and n) or CHO-745 cells (p g, h, o and p) 
that had been treated with 200 mU/ml neuraminidase (i-p) or were untreated (a-h). 
Cells were analyzed at 8 h post infection by immunofluorescence microscopy using an 
anti-S1 monoclonal antibody to detect IBV infection (b, d, f, h, j, l, n and p) and nuclei 
counterstained with Hoechst 33258 (a, c, e, g, i, k, m and o) 
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To confirm a general role for sialic acid in IBV infection, we analyzed infection by 
IBV M41 and Beaudette of chicken embryo kidney (CEK) cells that had been treated 
with NA. Cells were infected with approximately 1 FFU/cell IBV Beaudette or IBV 
M41, and in both cases pre-treatment of cells with NA reduced infection to 
undetectable levels compared to untreated cells (Fig. 4.7). Identical results were 
obtained with primary CK cells (data not shown). Overall, these data confirm a 
general role for sialic acid as an attachment factor for IBV, acting in concert with 
specific HS-mediated binding of IBV Beaudette.  
Figure 4.7. Neuraminidase treatment prevents IBV M41 and Beaudette infection 
of primary chick cells 
 Approximately 1 FFU/cell IBV Massachusetts 41 (M41) (a and b) or  Beaudette 
(Bddte) (c and d) was used to infect primary chick embryo kidney (CEK) cells that 
had been treated with 200 mU/ml neuraminidase (b and d)) or were untreated (a and 
b)). Cells were analyzed at 8 h post infection by immunofluorescence microscopy 
using an anti-S1 monoclonal antibody to detect IBV infection. 
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Discussion  
IBV Beaudette is an embryo-adapted avian coronavirus with an extended host 
range in cell culture. We show here that this extended tropism may in part be due to 
the use of HS as a selective attachment factor; excess soluble heparin competed with 
IBV Beaudette infection. Excess soluble heparin competed with IBV M41 infection. 
HS is well established as a cofactor in entry of a wide variety of viruses (28,32). 
However the levels of heparin needed for inhibition of IBV Beaudette infection were 
relatively high (approximately 12 mg/ml), which is significantly higher than for other 
viruses where heparin typically gives inhibition of infectivity, for example with 
Dengue virus and herpes simplex virus (27,41). However, in other cases, virus binding 
is only inhibited by high levels of heparan sulfate, e.g., a human rhinovirus type 89 
variant was inhibited at heparin concentrations of 2 mg/ml (38) and adeno-associated 
virus type 3H required pretreatment of cells with 50–100 mg/ml to prevent infections 
(4). Our data indicate that the affinity of IBV Beaudette–HS interactions is quite low. 
However, owing to the multivalent nature of virus–cell interactions, it is not possible 
to determine a value for this low-affinity interaction. 
To further characterize the heparin binding of IBV Beaudette, we carried out 
experiments with CHO cells that are deficient in HS/GAG expression, as well as 
carrying out experiments on BHK cells where surface HS was enzymatically removed 
with heparinase treatment (data not shown). However, in contrast to the situation 
where the virus receptor–binding sites are blocked by excess soluble heparin, we 
believe that the absence of HS/GAG on the cells surface can expose additional binding 
sites for the virus (i.e., sialic acid), and so these treatments do not inhibit infection 
with IBV Beaudette. In other words, blockage of a HS-binding site on the virus is not 
equivalent to removal of HS from the cell surface. 
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One distinctive feature of IBV Beaudette that may account for the specific 
interaction with HS is the presence of a novel sequence (SRRKRS or SRRRRS) 
between residues 686 and 691, which fits the heparin-binding consensus sequence of 
XBBXBX, where B is a basic residue and X is any amino acid (6). This consensus 
was present in all Beaudette sequences available in the database but not present for 
any other IBV strain analyzed. It is presently unclear whether this sequence is 
responsible for HS binding of IBV Beaudette. The consensus sequence identified by 
Cardin and Weintraub is based on the assumption that all GAG-binding proteins 
interact with the same oligosaccharides within heparin, a strategy that has been 
suggested to be overly simplistic (37). In fact examination of the consensus binding 
sites for heparin in basic fibroblast growth factor turned out to be incorrect once the 
crystal structure was determined. In the case of IBV Beaudette, the SRRKRS or 
SRRRRS motif is actually present in the S2 domain of the spike protein and not the S1 
domain typically associated with receptor interactions. However, in the absence of 
detailed structural information, it cannot be ruled out that this region of S2 (between 
686 and 691) is not exposed for use in viral attachment; the use of this as a receptor-
binding site awaits experimental analysis. 
As shown recently by Winter and colleagues (40), we confirm that sialic acid is an 
attachment factor for both IBV Beaudette and M41 and likely acts in a similar manner 
for all IBV strains. This is unusual, since most IBV strains do not ordinarily 
hemagglutinate red blood cells unless the virions themselves are pretreated with NA 
(3,9,33), and IBV Beaudette does not hemagglutinate red blood cells at all (3). Unlike 
some other coronaviruses that use sialic acid receptors, IBV does not encode a 
hemagglutinin-esterase protein that might act to cleave the receptor moities and allow 
efficient virus release and spread (8). Ultimately it is likely that despite acting as low-
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affinity attachment factors, neither HS nor sialic acid comprise the critical receptor for 
IBV entry into cells. The identification of this receptor is currently unknown. Like 
Winter et al. (40), we have been unable to rescue IBV M41 infection in BHK cells by 
expression of feline or human aminopeptidase N (J. Aronson, V. Chu, and G. 
Whittaker, unpubl. data), suggesting that aminopeptidase N is not a functional IBV 
receptor. The entry and receptor binding of IBV is likely to be complex process, and 
the specific use of HS by IBV Beaudette clearly demonstrates one important piece of 
the complex picture for IBV entry—the initial use of heparin sulfate by IBV 
Beaudette, which may play a critical role in the pathogenesis and host range of the 
virus. It is presently unclear whether HS binding accounts for differential tissue 
tropism of IBV Beaudette within the infected embryo, in addition to its possible role 
in extended species tropism. Experiments to determine the role of HS for IBV 
Beaudette of the chick embryo are currently underway. 
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SUMMARY AND CONCLUSIONS 
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Coronaviruses like SAR-CoV have had a negative impact on humans while the 
poultry industry has suffered financial losses due to the avian coronavirus IBV. In 
both cases, coronaviruses utilize their envelope spike glycoprotein S to gain entry in to 
the target cell. The S protein binds to a host cell receptor and this triggers 
conformational changes that make the S protein fusion ready. The S protein, a class 1 
fusion protein is capable of juxtaposing, destabilizing and fusing viral and host 
membranes. The coronavirus S protein has been the topic of a lot of research 
especially since the SARS outbreak, I have set out to characterize domains in S protein 
of the avian coronavirus the infectious bronchitis virus (IBV) and the severe acute 
respiratory coronavirus (SARS-CoV) utilized for entry.  
In Chapter 2, we introduce residues S798 to F815 corresponding with the S 
protein sequence as a putative fusion peptide. The region of the S protein was in close 
proximity to a newly identified cleavage site within S as well as highly conserved 
across the coronavirus family. Our studies showed that key conserved residues: L803, 
L804, F805 were important for fusion assays. Point mutants of the key residues 
drastically altered the fusiogenic potential of S in cell-cell fusion assays. Also in the 
pseudo-viral infection assays we observed that while pseudo-particles bearing the 
wildtype S were able to infect cells either at the cell surface or by the endosomal 
pathway, the pseudo-particles bearing point mutants of the key residues could not 
afford the same level of infection. We also took our studies a step further to show that 
synthetic peptides corresponding to the wildtype putative FP sequence were able to 
interact with membranes in a manner that promotes fusion and lipid mixing between 
labeled and unlabelled liposomes, while mutants peptides corresponding to the 
conserved residues highlighted in both cell-cell fusion and pseudovirus infection 
assays could not fuse.   
  119 
In chapter 3, we try to extend our understanding of the requirements for S 
mediated membrane fusion. We introduce conserved cysteine flanked domain (CFD) 
that we propose is part of the part of the machinery responsible for relaying the 
message of fusion. We hypothesize that the mechanism by which the signal for fusion 
is relayed within S might include cysteine disulfide loops formed between the flanking 
residues. Through mutations and deletions to the CFD, we were able to assay for 
function in fusion and infection assays, to demonstrate the importance of this region. 
Finally in chapter 4, we investigated the possible role of heparan sulfate (HS) a 
Glycosaminoglycan (GAG) as possible attachment factor for IBV. We observed that 
in the S protein of the IBV Beaudette, an avian coronavirus with extended host range 
was the presence of a novel sequence (SRRKRS or SRRRRS) between residues 686 
and 691, which fits the heparin-binding consensus sequence of XBBXBX, where B is 
a basic residue and X is any amino acid. We set out to show that this extended tropism 
might be due to the use of HS as a selective attachment factor with the use of soluble 
heparin in competitive infection assays and CHO cells deficient in HS/GAG 
expression. 
In terms of the current state of affairs regarding S protein mediated CoV entry, 
our studies though quite recent, have been met with consensus in recent literature. 
Most interesting is the consensus idea on the importance of the role of cleavage in the 
activation of the spike protein for membrane fusion (3, 4). Even better is the 
observation that the cleavage occurring directly upstream of our proposed fusion 
peptide has been implicated to be important for fusion in the avian coronavirus IBV 
(5). Also in unpublished data from our lab we observe an interesting flexibility in 
cleavage of the region N-terminal to the proposed fusion peptide. The indications from 
the results might further support the argument that this fusion peptide region might be 
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internal and a host of proteases can act on the spike either in close proximity to the 
fusion peptide or further upstream akin to the same situation observed in ASLV or 
EBOV. 
With all indications in the literature on the need for proteolytic activity for S 
protein function in membrane fusion and particularly as observed in IBV, it is more 
possible that our initial assessment of the region of the IBV Beaudette S protein as 
having a heparin sulfate (HS) binding site might take a backseat to the observation that 
the region is a designated furin cleavage site. We are already familiar with the 
advantage of furin cleavability and heparin sulfate binding in CoVs (1, 2) so it is 
possible that this novel region might work to extend the host range through HS 
binding and then increase cell-cell spread through furin cleavage. 
Future Directions 
In Chapter 2, we put forth a significant argument why the region S798-F815 
corresponding to the S2 portion of the SARS-CoV could be a coronavirus fusion 
peptide. In support of our claim, we observed that mutations made to select residues 
within the proposed sequence and in the context of the full length fusion protein 
showed decreased fusion activity and the synthetic peptides to the fusion peptide could 
promote fusion.  
A possible step to conclusively prove that this is the fusion peptide would be to 
show experimentally that cleavage exposes this fusion peptide.  An antibody prepared 
against the fusion peptide can be used to detect the exposure of the fusion peptide 
upon cleavage. Also if the antibody is able to block infection, it can be proposed that 
the antibody inhibits the fusion peptide from properly inserting in to the host 
membrane. Also confirmation that the fusion peptide actually interacts with the host 
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membrane in context with the full length fusion protein can be achieved by identifying 
sequences that can be labeled by cross-linking probes embedded in the target 
membrane. All these suggestions are currently being pursued in our laboratory. 
Finally, it is my belief that we stand to gain a lot of information if the structure 
of the S protein can be solved as we have benefited immensely from the amount of 
information gained from solved structures of other viral protein. Ultimately a solved 
structure would help shed light on the claims put forth in its absence and perhaps 
further aid in the development of potent therapeutics. 
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